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     ABSTRACTS 
Introduction: The focus of this study is to identify the potential prognostic factors and 
symptoms that are associated with Cryptococcal Meningitis and to establish a statistical 
model for the prediction of outcomes (survival and mortality) among in-hospital patients. 
Materials and Method: The hospital admission books in the medical wards and pharmacy of 
the East London Hospital Complex were searched to identify the folder numbers of all the 
patients that were admitted, diagnosed and or treated for Cryptococcal Meningitis at the 
hospital between the 1
st
 of January 2009 and the 31
st
 of August 2012. 237 folders out of 519 
folders reviewed had confirmed cases of Cryptococcal Meningitis. Data on patients’ 
demographics, In-hospital care, and Concurrent infection/health condition were collected and 
analysed in a cross-sectional study, using the univariable and multiple logistic regression. 
Analysis of data was done with SAS version 9.1.3 and NCSS version 2007 software. 
Results: In a multivariable logistic analysis of variables found to be significantly associated 
with Cryptococcal Meningitis in a univariable logistic regression, Being Conscious (i.e. a 
Glasgow Coma score of 15) (OR= 5.34,CI=2.85-9.99 p =<0.000); Having no history of TB 
infection (OR=28.91, CI= 3.68-226.89, p = <0.001); No Fits (OR = 2.59, CI= 1.18-5.68 p = 
0.017); Being a non-smoker (OR =2.22,CI=1.13-4.34 p = 0.020); and Adhering to treatment 
instruction and guidelines (OR = 2.38, 1.15-4.89, p = 0.019) were the variables found to be 
significantly associated with the survival of a Cryptococcal Meningitis patient.  The 
uninterrupted use of Amphotericin B (OR=3.04, CI=1.06-8.72, P=0.038) as a first line 
regimen was also found to be significantly associated with survival. 
On the other hand, being unconscious (i.e. Glasgow Coma score <15) (OR =5.34, CI=2.85-
9.99, p = < 0.000), Currently having a TB infection (OR = 9.20, CI=2.77-30.57, p = < 0.000), 
Not adhering to treatment guidelines (OR=2.38, CI=1.15-4.89, p=0.019 ); Being a smoker 
(OR = 2.22, CI=1.13-4.34, p = 0.020) and having Fits (OR=2.59 CI=1.18-5.68 p=0.017 ) 
were found to be significantly associated with mortality. Headache (p= 0.505) was found not 
to be a significant predictor of survival contrary to the findings in many publications on 
Cryptococcal Meningitis.  
 Owing to time constraint, testing data was not collected to validate the prognostic models. 
However, model diagnostics was done and the relevant statistics confirmed the goodness of 
fit and the predictive ability of the model 
      v 
Conclusion: It has been established in this study that certain baseline variables can be helpful 
in the prognosis of Cryptococcal Meningitis infection. It is therefore believed that these 
variables will help in improving the prognosis of the infection especially at the East London 
Hospital Complex. Though the statistical models will work well in predicting the outcome of 
Cryptococcal Meningitis infection for patients admitted at the East London Hospital 
Complex, adequate precaution must be exercised while attempting to apply it in other 
geographical areas.    
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     CHAPTER ONE                     
1.0 INTRODUCTION: 
This dissertation presents a retrospective clinical study conducted using data obtained from 
the medical folders of patients diagnosed and treated for Cryptococcal Meningitis at the East 
London Hospital Complex facilities from the 1
st
 of January 2009 to August 2012. To proceed 
with this study, a waiver of informed consent was considered necessary due to the difficult 
nature of tracing individuals whose medical data are been kept in the hospital. 
It is our belief that this research produced valuable information that will improve patient care 
in the future. Throughout this study, more and better understanding of the prevalent 
symptoms and prognostic factors associated with Cryptococcal Meningitis were sought. In 
doing this, certain variables which were indicted in previous studies within and outside South 
Africa as well as those which in our own view are possible risk and prognostic factors were 
considered. The variables measured in this study consist of those relating to the Demographic 
and Clinical characteristics, Process of Care; and Severity of the disease measured with the 
patients’ level of consciousness.  
The study did not make use of interventions or questionnaires. However, Case Record Forms 
(CRF) referred to as data extraction forms were used for the extraction of relevant 
information from the patients’ folders.  
Data extracted from the folders were cross-checked for correctness and completeness before 
proceeding with the data analysis. Data analysis was performed using SAS version 9.1.3 and 
NCSS 2007. The steps followed in the analysis are discussed in the Data Analysis section. 
 
1.1 Why Cross-Sectional Study? 
A cross sectional study was preferred for the following reasons:  
 The study made use of data collected at a defined time. 
 The study did not consider repeated measurements and time to event outcome. 
 The period for the study was short and resources were minimal. Cross sectional 
studies are less expensive and quick to carry out. 
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 The study used previous information from the patients’ medical records.  
 The study utilized all available data within the period under study to eliminate bias 
and improve on the quality of the study result. 
 The study looked at the relationship between the in-hospital treatment outcome for 
Cryptococcal Meningitis patients and other variables of interest using single point 
measurement preferably the baseline measurement. (Piantadosi, 2005)  
1.2  Research Objective 
The primary objectives of this study are as follows: 
 To identify the outcome predictors for Cryptococcal Meningitis. 
 To identify the predominant presenting symptoms among patients with Cryptococcal 
Meningitis in the study. 
The secondary objective is to examine the extent of conformity of the results of this study 
with that of the previous studies. 
 
1.3 Research Questions: 
This study is guided by the following research questions: 
 What are the outcome predictors of Cryptococcal Meningitis among the patients’ 
whose information were included in this study? 
 What are the predominant presenting symptoms indicative of Cryptococcal 
Meningitis among these patients? 
 Does the result from 1 and 2 confirm the correctness of similar studies done 
elsewhere?  
1.4 Motivation: 
From the words of Ioannidis, J P A, (2000) came the motivation for this study as follows, 
“There is increasing concern that most current published researched findings are false... The 
probability that a research claim is true may depend on study power and bias, the number of 
other studies on the same question, and importantly the ratio of true to no relationships 
among the relationships probed in each scientific field. In this framework, a research finding 
is likely to be false when the studies conducted in a field are smaller; when effect sizes are 
smaller; where there is greater flexibility in designs, definitions, outcomes, and analytical 
models; when there is greater financial and other interest and prejudice; and when more 
teams are involved in a scientific field in chase of a statistical significance”  
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Further motivation came from the belief that the incidence, symptoms and risk factors of CM 
vary from one geographical area to another and this is a concern that needed all hands on 
ground to verify. More so, as a major opportunistic infection in AIDS patients which 
Antinorio, S; Ridolf, A; Fasan, M; Maqni, C; Galiberti, L; Milazzo, L; et al, (2009) believed 
has an estimated 957 900 cases and 624 700 deaths by 3 months after infection occurring 
each year particularly in resource limited settings, it becomes a critical area for research 
study.  
Although Salima, et al., (2011) observed that early detection and treatment of Cryptococcal 
Meningitis can be helpful in reducing mortality, actualizing such result becomes impossible 
without a formidable knowledge of the dominant variables influencing the infection (based 
on researched studies and not myths) communicated to the population at risk of the infection. 
Moreso, it is glaring from the findings of Salima, et al., (2011); P, Mwaba; et al, (2001); 
Lightowler, J V J; Cooke, G S; Mutevedzi, P; Lessells, R J; Newell, M L; et al, (2010); 
Niranjan, N Singh et al, (2011), French, N; Gray, K; Watera, C; Nakiyingi, J; Lugada, E; et 
al, (2002); Millogo, A; Ki-Zerbo, G A; Andonaba, J B; Lankoande, D; et al, (2004) and 
Maher & Mwandumba, (1994) that presenting symptoms of CM differ in proportion and 
order of presentation from one geographical setting to the other. Based on this fact, it will be 
improper to educate people at risk of this disease based on results from studies carried out in 
other geographical areas. 
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Figure 1.1: Map of South Africa showing its Provinces and Cities  
 
Source: www.mapsopensource.com 
Finally, literature search revealed that there has not been any published work done on the 
prognostic factors and symptoms associated with Cryptococcal Meningitis in the Eastern 
Cape of South Africa as at the time this study commenced, hence the need to carry out this 
study. 
 
1.5 Scope of Investigation: 
The study focuses on identifying the potential prognostic factors and symptoms associated 
with Cryptococcal Meningitis. It also aims at building a statistical model that will explain the 
relationship between CM outcomes and some prognostic factors observed among in-hospital 
patients at the East London Hospital Complex in South Africa. Data for this study comprised 
of baseline measurements recorded for each patient at the time of admission from the 1
st
 of 
January 2009 to 31
st
 of August 2012 and were extracted from their medical folders by trained 
medical data capturers within a period of two months.  
Analysis of data was done using SAS Version 9.1.3 and NCSS 2007. The univariable and 
multivariable logistic regression were used in the analysis. 
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      CHAPTER TWO                                
2.0 LITERATURE REVIEW 
This chapter provides information on the strategy for literature search. It further reviewed 
previous publications on Cryptococcal Meningitis and prognostic factor analysis. It presented 
the views of various authors on this subject and evaluated them in the context of this study. 
Notes were also taken of the methodologies applied and its short comings.  
 
2.1 Strategy for Literature Search: 
Electronic and non-electronic sources of academic information and literatures were searched 
using the following key words in different combinations: Cryptococcus neoformans, 
Cryptococcal meningitis, Prognostic factors, Symptoms, Outcome predictors, HAART, 
HIV/AIDS, Retrospective studies. The results from these searches provided access to several 
related studies, publications and materials from the World Health Organisation (WHO), 
Centre for Disease Control (CDC), Centre for Infectious Diseases (CID) in Kaplan, et al., 
(2002) and the National Institute of Health (NIH). The guideline for prevention, diagnosing, 
treatment and management of CM in South Africa as presented in Kerrigan, McCarthy; et al, 
(2007) was also consulted.  
 
2.2 Literature Review: 
Cryptococcal Meningitis is a common opportunistic infection in AIDS patients, particularly 
in Southeast Asia and Africa. (Tihana & Thomas, 2004). It is prevalent in immuno-
compromised individuals and ubiquitous in distribution. (Kanchan, M; et al., 2012). It is 
believed that the rise in global incidence of Cryptococcal Meningitis has a strong association 
with HIV/AIDS epidemic. (John, 2011). People living with HIV/AIDS or receiving 
immunosuppressive drugs after an organ transplant are believed to be at a higher risk of 
contracting CM. (Knoke & Schwesinger, 1994). According to McCarthy, K M; Morgan, J; 
Wannemuehler, K A; Mirza, S A;et al, (2003), 97% of Cryptococcosis cases present with 
meningitis
 
and often lead to a situation where Cryptococcosis is mostly used interchangeably 
with Cryptococcal Meningitis. (Kerrigan, McCarthy; et al, 2007). Buchanan & Murphy, 
(1998), observed that the rate of global incidence of Cryptococcal Meningitis has been on the 
rise since 1980 contrary to the expectation that with the advent of the HAART, incidence,  
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mortality and morbidity resulting from Cryptococcal Meningitis will be on the decline. To 
further confirm the observation made by Buchanan & Murphy, Sloan, et al., (2008) reported 
that despite the advent and increasingly wide availability of antiretroviral therapy for people 
with HIV/AIDS, Cryptococcal Meningitis remains a significant cause of death and illness 
amongst individuals with HIV infection in resource limited settings; and the ideal way to 
manage the disease remains unclear. 
 
  Figure 2.1: Cryptococcus neoformans stained with Indian ink 
                                                       
                                    Source: www.sequence.stanford.edu 
 
Figure 2.2: Diagram showing the Transmission Cycle of Cryptococcus Neoformans. 
           Source: http://www.bmolchem.wisc.edu/labs/hull/images/figure1jpg 
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2.2.1 International Treatment Guideline for Cryptococcal Meningitis 
 
The optimal therapy for treating and managing Cryptococcal Meningitis in HIV-Infected 
individuals is: AmBd 0.7-1mg/kg/day intravenously plus flucytosine 100mg/kg/day orally in 
4 divided doses for 2 weeks; intravenous formulations may be used in severe cases and in 
those without oral intake where the preparation is available; followed by fluconazole 
400mg/day for 8 weeks and 200mg/day thereafter.  (Tihana & Thomas, 2004), (Perfect; et al, 
2010). However, there are also international guidelines for the treatment of the disease in 
resource-limited societies where flucytosine is not available or unaffordable. In such settings, 
the treatment starts with an induction therapy of AmBd 1mg/kg/day IV for 2 weeks or AmBd 
0.7mg/kg/day IV plus fluconazole 800mg/day orally for 2 weeks followed by consolidation 
therapy with fluconazole 800mg/day orally for 8 weeks. Maintenance therapy is fluconazole 
200-400mg/day orally until immune reconstitution. (Perfect; et al, 2010). 
McCarthy, K M; Morgan, J; Wannemuehler, K A; Mirza, S A;et al, (2003) and Park et al, 
(2009), called for improvement on the early recognition, diagnosis and treatment of the 
disease especially among the economically-impoverished nations, as this may allow for 
fluconazole (a commonly available therapy) to be used as the first-line therapy with better 
and favourable outcome.   
 
2.2.2 Challenges Facing the Fight against Cryptococcal Meningitis 
 
The pandemic of AIDS has led to a rise in the incidence of Cryptococcal disease and a 
reduction in the average age of affected patients. In Kanchan, M; et al., (2012), HIV was 
100% pre-disposing factor for CM and 68% pre-disposing factor in Moosa & Coovadia, 
(1997). For South Africa, with a high prevalence rate of HIV, this should be a big concern. 
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Table 2.1: HIV Prevalence Estimates and Number of People Living with HIV in South 
Africa, 2001-2011 Prevalence. 
 Incidence  HIV population 
Year  
Adult 15-49  Adult 15-49  Total population  Adult 15-49 (millions) 
2001  
1,72  16,0  9,4  1,72  4,21  
2002  
1,59  16,2  9,6  1,59  4,37  
2003  
1,58  16,2  9,7  1,58  4,49  
2004  
1,63  16,2  9,8  1,63  4,59  
2005  
1,73  16,2  9,9  1,73  4,69  
2006  
2,11  16,6  10,2  2,11  4,87  
2007  
1,54  16,5  10,2  1,54  4,95  
2008  
1,43  16,4  10,3  1,43  5,02  
2009  
19,1  16,4  10,4  1,45  5,13  
2010  
19,3  16,5  10,5  1,43  5,26  
2011  
19,4  16,6  10,6  1,38  5,38  
  Source: Statistics South Africa 2011 
Socio-economic factors, poverty and poor sanitation are possible contributory factors to the 
incidence of CM infection. (Hakim, J G; et al, 2000), (P, Mwaba; et al, 2001). 
Kambugu, A; Meya, D B; Rhein, J; O'Brien, M; Janoff, E N; et al, (2008), added that cultural 
bias is a major impediment to the fight against CM in Uganda.
  
Patients and their families are 
biased towards giving consent for the Lumbar puncture (which is an important procedure in 
controlling the patient’s pressure) and only allow it at near-death or near-comatose situations.  
Lastly, the issue of patients’ adherence to treatment as raised by Collett & Parrish, (2007) has 
presented the efforts dispensed towards the fight against CM with tough challenges. 
According to them, emphasis should not be limited to the roll-out of medication but also on 
the quantification of sustained clinical benefits.  
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Table 2.2: Number of Cases and Incidence of Cryptococcal Disease reported to Germs-SA by   
                   Province, South Africa, 2010 and 2011, N=13803 
 
PROVINCE 
                        2010                          2011 
              N INCIDENCE
** 
              N INCIDENCE
** 
EASTERN CAPE 1330 20 1236 18 
FREE STATE 457 16 357 13 
GAUTENG 2099 19 1938 17 
KWAZULU NATAL 962 9 1037 10 
LIMPOPO 568 10 417 8 
MPUMALANGA 703 19 597 16 
NORTHERN CAPE 63 6 66 6 
NORTH WEST 532 17 453 14 
WESTERN CAPE 490 9 498 9 
SOUTH AFRICA 7204 14 6599 13 
SOURCE: GERMS-SA Annual Report 2011.  ** Incidence rates were calculated based on population 
                   denominators provided by Statistics South Africa, and expressed as cases per 100,000. 
 
2.2.3 Prognostic factors: 
The word “Prognosis” originated from the Latin word progignoskein which means “to know 
before” and its first known use was in 1665 and can therefore be understood as the act or art 
of foretelling the course of a disease. It can also be seen as the prospect of survival and 
recovery from a disease as anticipated from the usual course of that disease or indicated by 
special features of the case. Prognosis furthermore can be seen as a prior knowledge of the 
outcome of a disease.  
For us to determine how a disease is likely to behave, with or without treatment, certain facts 
about the disease must be known and these facts are referred to as prognostic factors. The 
factors that predict for better outcome are called good or favourable prognostic factors while 
those that predict for worse outcomes are called poor prognostic factors.  
Manisha, Juthani-Mehta; Vincent, J Quagliarello, (2004), stated in their publication that there 
are three generic categories on which prognostic estimates can be based: Demographic and 
Clinical characteristics; Process of Care; and Severity of Disease. These prognostic estimates  
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of clinical outcomes can be useful in making therapeutic decisions; Site care and Family 
counselling. However, designing an accurate and reliable prognostic model for an infectious 
disease may present some bits of challenges due to its requirement to collect detailed clinical 
data from large cohort of patients with clinically relevant outcome assessment.  
Piantadosi, (2005) gave an elaborate approach to Prognostic Factor Analysis (PFA). 
According to him, a valid prognostic factor analyses should be based on the absence of strong 
selection bias, correctness of the statistical models used, observing, recording and analysing 
the important predictor variables correctly. It provides useful information on the past, present 
and future and is beneficial in understanding the relative importance of several variables 
associated with a disease outcome which is an important tool in designing clinical trials.  
2.2.4 Some Previous Prognostic Studies on Cryptococcal Meningitis and their findings 
Prior to the HIV epidemic, prognostic factors predicting poor outcome in CM include: The 
underlying disease, no headache, abnormal mental status, high organism burden, poor host 
inflammatory response and raised CSF opening pressure. Visual changes, headache on 
presentation and employment in the mining industry were on the other hand found to be 
factors associated with survival (Tihana & Thomas, 2004), (McCarthy, K M; Morgan, J; 
Wannemuehler, K A; Mirza, S A;et al, 2003), (Lortholary, O; Poizat, G; et al, 2006). 
Although many publications like Park et al, (2009) and Lightowler, J V J; Cooke, G S; 
Mutevedzi, P; Lessells, R J; Newell, M L; et al, (2010) observed no racial differences with 
respect to incidence of CM, others like Judith & William, (2006); Pinner, et al., (1995) and 
De Wyth, et al., (1982) believed that the incidence is higher among the blacks and aborigines.  
Many other studies like Salima, et al., (2011) and S, H Lan; et al., (2001) found that socio-
economic status is also a factor influencing the incidence of Cryptococcal Meningitis.  
While Kris Ann, et al., (1999), found that steroid use is not associated with increased risk of 
CM in HIV-infected patients, others like Judith & William, (2006) and Pinner, et al., (1995) 
found that injection drug use and cigarette smoking are risk factors for CM.  
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Baseline CSF CFU counts were also found to be important prognostic factor for CM.
 
(Brouwer, A E; Rajanuwong, A; Chierakul, W; Griffin, G E; et al, 2004). Many of the 
publications agreed that one of the ways to prevent infection is to avoid environments 
contaminated with pigeon droppings, suggesting that locality may be a risk factor. (Judith & 
William, 2006).  
The clinical presentation and course of CM vary, relating in part to underlying medical 
conditions (e.g. diabetes, sarcoidosis, glucocorticoid use) and the immune status of the host 
suggesting that HIV/AIDS, Diabetes and Lymphona can be risk factors. (David, Jatin, & 
David, 2012), (Pappas, P G; Perfect, J R; Cloud, G A; et al, 2001). 
 
Below are results from some studies done on CM within and outside of South Africa. 
 
Canessa, J; Cabrera, D; Eskenazi, J; Samalvides, F; (2011), in a case-control study aimed at 
determining the associated factors for in-hospital mortality among patients with Meningeal 
Cryptococcosis and HIV infection, reviewed the medical histories available at a local hospital 
in Lima and used the logistic model to determine the factors associated with mortality among 
90 patients of which 37 were deceased and 53 surviving patients. According to their findings, 
Glasgow at admission (OR = 4.55 (1.61 – 12.20), p = 0.01) and Serum antigen titer greater 
than 1024 (OR = 20.48 (1.6 – 261.04, p = 0.02) were found to be associated with mortality.  
Also, Edward, R C; et al, (2010), examined 82 patients of which 80 of them were presented 
with complicated Cryptococcal Meningitis and found no difference in age, gender, 
race/ethnicity, HIV risk factor, CD4 cell count or HIV plasma load between patients with and 
without complicated CM. They found that patients with complicated CM had higher 
frequency of baseline focal neurological findings (50 vs. 5%, p = 0.0001), head Computed 
Tomography (CT) abnormalities (21 vs. 2%, p = 0.03) and mean values of CSF opening 
pressure, (43 vs. 27 cmH20, p = 0.0001).  
Furthermore Kris Ann, et al., (1999), carried out a nested case-control study of 37 incident 
cases of CM and 74 controls, identified from a cohort of more than 2000 HIV-infected 
patients. Conditional logistic regression was used to study demographic and AIDS-related 
variables in addition to fluconazole and steroid use. They found no difference between cases 
and control in demographic variables, HIV risk factors, or stage of AIDS. According to  
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their study, exposure to fluconazole for more than 90 days reduced the risk of CM by 82% 
(OR = 0.18; 95% CI = 0.04-0.85; p = 0.03) and they found no difference in steroid use 
between cases and controls for either the length or amount of steroid exposure (p = 0.41). No 
difference was observed in survival during follow-up in the clinic using the log-rank test (p = 
0.74). Among the cases, a Cryptococcal antigen was positive in more than 97% of the CSF or 
blood samples. CSF and blood cultures were positive in 81 and 44% of the samples, 
respectively. They concluded that demographic factors do not affect the risk of Cryptococcal 
Meningitis in an inner city United States population and steroid use was not associated with 
an increased risk of Cryptococcal Meningitis in HIV-infected patients.  
Again Lightowler, J V J; Cooke, G S; Mutevedzi, P; Lessells, R J; Newell, M L; et al, (2010), 
found that in a multivariable Cox regression analysis of CM patients in Kwazulu Natal, focal 
neurology (aHR 11 95%C.I. 3.08–39.3, P<0.001), diastolic blood pressure <60 mmHg (aHR 
2.37 95%C.I. 1.11–5.04, P = 0.025), concurrent treatment for tuberculosis (aHR 2.11 95%C.I. 
1.02–4.35, P = 0.044) and use of fluconazole monotherapy (aHR 3.69 95% C.I. 1.74–7.85, 
P<0.001) were associated with increased mortality at 14 and 28 days of follow up. 
 
 
Finally Mohammed & Chandrasekhara, (2009), carried out a study on Cryptococcal 
Meningitis in HIV Seropositive Patients and found that altered sensorium and CD4 count of ≤ 
50 was associated with poor prognosis.  
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          CHAPTER THREE                       
3.0 RESEARCH DESIGN AND METHODOLOGY 
This chapter provides information on the research processes and procedures. It deals with the 
process of data collection, ethical issues and the technique for analysis. Conscious efforts 
were made to explain these techniques so as to provide the reader with better understanding 
of the direction of view in this study 
 
3.1 Research Design: 
To assess the effects of prognostic factors, a statistical model providing the mathematical 
relationship between the predictors on one hand and the outcome on the other hand is used. 
These statistical models are designed to combine theoretical knowledge with empirical 
knowledge and were made to adhere to the following steps as provided by Piantadosi, (2005): 
There was a combination of clinical and statistical knowledge. Hence, the model building 
was not solely based on the output of the analytic software as most built-in procedures 
designed for the selection or elimination of variables in some of the softwares during model 
building may be inappropriate. 
Proper procedure was followed in resolving the challenges posed by missing data in the 
analysis. 
The importance or relevance of each of the factors or variables recorded were examined in a 
univariable logistic regression analysis. 
Relevant or significant variable factors were used in building the multivariable logistic 
regressions. Also, the predictor variables were checked to determine their strength of 
association with one another. This is necessary to avoid the problem of multicollinearity in 
the model.  
This research study understands that model validation is necessary but could not carry it out  
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due to time constraint. Model validation will require the collection of a testing data which at 
this time is not possible due to time constraint and unavailability of the needed resources. 
However, model validation will help us understand how well our model will function for a set 
of data different from the ones for which it was constructed with.  
A multivariable logistic procedure involving several predictors and a binary outcome 
(survival and mortality) was followed. For the study data having categorical dependent 
variable the logistic regression or the Discriminant analysis becomes the optimum choice for 
data analysis. However, the Discriminant analysis model uses the distribution of the 
predictors to make its assumption and does not accept qualitative predictor variables as 
present in the study data set. This implies that with a binary qualitative response variable and 
categorical ordinal and nominal predictors; multivariable logistic regression becomes a 
suitable technique to apply. Moreover, the proportional hazard regression cannot be used here 
since this study is not concerned with time-to-event analysis. 
Despite the flexibility of the Logistic regression, the technique require a minimum of 50 
observations or data points for each predictor in order to achieve a stable result. (David D. , 
2007).  
Mohammed & Chandrasekhara, (2009); Kris Ann, et al., (1999); Edward, R C; et al, (2010); 
Canessa, J; Cabrera, D; Eskenazi, J; Samalvides, F;, (2011), used the logistic regression in 
their Prognostic Factor Analysis (PFA) of Cryptococcal Meningitis data in their studies. 
Although their data did not meet the requirement above, yet they achieved reasonable results. 
Beyond Cryptococcal Meningitis, Multivariable logistic regression has been used extensively 
for Prognostic Factor Analysis PFA involving Cancer, Eye Care, and HIV/AIDS. (G, Stoter; 
et al, 1987), (Nakanishi, H; Kuriyama, S; Saito, I; et al, 2008), (Berhe, Amanuel, & Yilma, 
2012). 
 
3.1.1 The Logistic Regression: 
The challenges of devising a more efficient mathematical function for population growth 
study gave birth to the logistic function in the 19
th
 century. Although its original intention 
was for population growth studies, it also had its application in autocatalytic reactions. Major  
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contribution to the development of this function was made by Pierre-Francois Verhulst who 
lived from 1804 to 1849.  He gave the name Logistic Function to this function and also 
provided a detailed account of the function and its properties. He gave the function as:  
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The function was further developed for use in market penetration of new products and 
technologies. (Cramer, 2002).  
The application of the logistic function in Bio-assay was published by Winston and 
Worcester in 1943. (Wilson & Jane, 1943). 
According to Michael, (2010), Logistic regression is a statistical technique that estimates the 
natural base logarithm of the probability of one discrete event “Survival” occurring as 
opposed to another event “Death” or more other events. The log-odds of the event are the 
predicted values. 
One of the challenges in logistic regression is that of non-convergence. This can occur when 
a logistic regression has large proportion of variables to cases as a result of the overly 
conservative Wald statistic. In this situation, there are tendencies for the regression 
coefficients to remain unbiased, even as the standard error increases in the presence of an 
increasing multicollinearity. (Menard, 2002).  
Like every other model, the logistic regression is founded on some assumptions which 
include the following: 
 Logistic regression assumes a non-linear relationship between the dependent and 
independent variables, however its logit function is assumed to be linear. 
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It uses the maximum likelihood method as the criterion for best fit rather than the 
least square deviations. By using the maximum likelihood, the probability of getting 
the observed result given the fitted regression coefficients is maximized. A 
consequence of this is that the goodness of fit and overall significance statistics used 
in logistic regression is different from those used in linear regression 
 The dependent variable must be binary qualitative variable. 
 More samples are needed compared to the linear model. A minimum of 50 
observations for each predictor is preferable.  
 The assumptions of normality, linearity and equal variance in each group as required 
in linear models does not hold in the logistic regression model. 
 Each observation must belong to one category only. 
 
3.1.2 Technique for Analysis: 
As outlined in Piantadosi, (2005), the following procedures were followed: 
Nominal categorical data were coded using dummy variables. Also, variable names were 
coded to match the requirement of the SAS environment and the NCSS 2007. 
With due consideration for the binary nature of the response variable and the categorical 
predictors, multiple logistic regressions were used to formulate the PFA model using the 
NCSS 2007 after obtaining the result of the univariable analysis performed with the SAS 
Version 9.1.3 software.  
A combination of clinical, biological and statistical knowledge was employed in building the 
prognostic model. Dr Horsfall and Prof Parrish; the clinical heads of the Medical Department 
at Frere Hospital and CMH respectively were contacted in the course of this work in 
situations where clarity is required concerning clinical matters.  
All the identified relevant predictor variables were screened individually in a univariable 
analysis to determine its strength of association with the binary response variable (Survival 
and Mortality). This preliminary step was helpful in streamlining and ensuring that only the 
relevant variables were used in the multivariable logistic regression analysis.  
The forward hierarchical selection procedure was used to perform the model selection. 
Effects of multicollinearity and confounders were dealt with by separating strongly correlated 
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predictors in the model.  
According to Allison, (2012), multicollinearity is a common problem when estimating linear 
or generalized linear models, including logistic regression and Cox regression. It occurs when 
there are high correlations among predictor variables, leading to unreliable and unstable 
estimates of regression coefficients. However, there are several situations in which 
multicollinearity can be safely ignored. If the proportion of cases in the reference category is 
small, the indicator variables will necessarily have high Variance Inflation Factors (VIF’s), 
even if the categorical variable is not associated with other variables in the regression model. 
This implies that the p-values for the indicator variables may be high. But the overall test that 
all indicators have coefficients of zero is unaffected by the high VIFs. And nothing else in the 
regression is affected. Choosing a reference category with a larger fraction of the cases can 
help avoid high VIF’s. By so doing, situations where none of the individual indicators is 
statistically significant even though the overall set of indicators is significant can be avoided.  
 However, adequate care was taken to avoid the pitfall that comes with total reliance on p-
values for significance by giving consideration to the biological and clinical plausibility of 
the significant predictors. 
Owing to time-constraint imposed on this study, it was not possible to collect a testing data 
set for the model validation. However, the final log likelihood and ROC curves confirmed the 
goodness of the fitted model. 
 
3.2 Research Methodology 
Case Record Forms (CRF) was designed to collect baseline information with regard to the 
variables of interest within the period 1
st
 Jan 2009 to 31
st
 Aug 2012. The variables were 
chosen based on information obtained from previous research studies on Cryptococcal 
Meningitis within and outside of South Africa.   
 
3.2.1 Research tools:  
This study made use of data pre-extraction form and Case record form. The pre-extraction 
form was designed for use in perusing the admission books for patients’ folder numbers. To 
make work easy for the staff at the medical records office, the surname and initials of the 
patients were included alongside the folder numbers in the pre-extraction form. This was  
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done to control duplication of patients in our forms. On the Case Record Form, only the 
patients’ folder number was recorded alongside the Centre code to serve as identifiers. 
However, our tools proved effective all through the data collection exercise. 
 
3.2.2 Selection criteria: 
 All the folders reviewed met the following selection criteria: 
                INCLUSION CRITERIA                  EXCLUSION CRITERIA 
 The Patient was diagnosed, admitted 
and treated for CM at the East 
London Hospital Complex facilities 
within the period under review. 
  
 The patient was residing in the 
Eastern Cape, South Africa prior to 
the time of CM diagnosis.  
 The patient was diagnosed or treated 
for some disease other than CM at the 
East London Hospital Complex. 
 
 The patient was not admitted for CM 
at ELHC within the period 01-01-
2009 to 31-08-2012 
 
 The patient was not residing in the 
Eastern Cape prior to CM diagnosis 
 
3.2.3 Study Sites: 
This study took place at the East London Hospital Complex which comprises of: Frere 
Hospital and Cecelia Makiwana Hospital. The complex is overseen by an Executive 
Management Team comprising the Hospital Chief Executive Officer (CEO) and the Directors 
of Clinical Governance, Finance, Facilities and the Human Resource, Administration and 
Information Technology.  
 
Frere Hospital: 
Located in East London and founded in 1881, Frere hospital is the biggest hospital in Buffalo 
City metropolis. It is a level 1 tertiary hospital and has 857 usable beds.  
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Cecelia Makiwane Hospital: 
Established in June 1975 and situated at Mdantsane, Cecelia Makiwane Hospital is  
designated as a regional hospital with 737 usable beds. It was named after the first black 
South African who qualified and registered as a nurse (on the 1
st
 of Jan 1901) in South 
Africa. 
 
 
 
Table 3.1: Population of Districts overseen by the East London Hospital Complex 
DISTRICT MALE FEMALE TOTAL % OF TOTAL 
POPULATION 
VS EC 
Eastern Cape (EC) 3089701 3472353 6562053  
DC12: Amathole 419247 473389 892637 13.6 
DC13: Chris Hani 376638 418823 795461 12.1 
DC14: Joe Gqabi 165443 184325 349768 5.3 
BUF: Buffalo City 358557 396644 755200 11.5 
 1,319,885 1,473,181 2,793,066 42.5 
Source: 2012 South African Population Census Result from Statistics South Africa 
 
3.2.4 Sample Size 
Schmoor, et al., (2000), commenting on the sample size calculation for prognostic factor 
analysis stated that, “the existing sample size and power formulae cannot be valid and may 
not be applied in a prognostic factor analysis since the covariates are expected to be 
correlated with the factor of primary interest”. Also Piantadosi, (2005), observed that 
Prognostic Factor Analyses (PFA) most often, utilize all of the data that bear on a particular 
question or analysis.   
Based on the submissions above, this study made use of all available data within the period 
under review. Using all the data within the period under study was helpful in minimizing 
biasedness due to sampling and also improved the result. Hence, the 237 patients of whom 
the information on their folders met the inclusion criteria were all included in this study. 
However, consideration was given to 50 observations to a variable ratio, as required in a 
multivariable logistic regression. This study however had a maximum of 6 variables in the 
multivariable logistic regression and there were convergence for both models. 
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3.2.5 Identifying the Research Subjects: 
The study started with a pre-data collection which looked through the admission books at the 
medical wards. The Admission books contain patients’ demographic data, symptoms, name 
of sickness and outcome. The names of diseases recorded in the admission books are the ones 
known at the time of admission and may differ from the actual diagnosis which necessitated 
the patients’ hospital visit at this time. From these books, folder numbers of patients admitted 
with confirmed or queried cases of Cryptococcal Meningitis were copied.  
However, the main challenge here is that of patients admitted without any known sickness  
but symptoms. It is possible that some of such patients (especially those with first episode of 
CM) may in the course of medical tests and other diagnostic processes be found to have a 
CM infection. To overcome this situation, folder numbers of patients with presenting 
symptoms similar to that of CM were also copied for further verification from their medical 
folders.  
More so, to ensure that all cases of CM that fall within the time range for this study are 
included in this study, the In-patient pharmacy and the ARV pharmacies were approached for 
the Fluconazole register. This register maintains a database of fluconazole dispensing to CM 
in-patients and out-patients as well. Considering the guidelines for the treatment of CM, it 
will be an almost impossible procedure for a CM patient not to have fluconazole medications 
especially in the maintenance phase of the treatment guidelines. Admission books at the ICU 
and the Paediatric wards were also checked for CM patients’ at both hospitals. 
Through these processes, folder numbers of research subjects were identified, collected and 
sorted to avoid double or more entries.  
 
3.2.6  Sorting the folder numbers: 
Cryptococcal Meningitis, especially among HIV/AIDS patients is a life-long disease, with 
cases of relapse and repeated visits to collect medications. In some cases during in-hospital 
treatment, patients may need to be transferred from one ward to the other for some medical 
procedures. This creates a situation where a patient’s folder number appears repeatedly in 
various wards within the same period of admission. To deal with this situation, all collected 
and recorded folder numbers were tabulated and sorted using the excel data sorting tool. The 
sorted folder numbers were submitted to the medical records office for the retrieval of the 
folders. 
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3.2.7 Folder retrieval and data collection: 
From Responsible Conduct in Data Management, Data collection is the process of gathering 
and measuring information on variables of interest, in an established systematic fashion that 
enables one to answer stated research questions; test hypotheses; and evaluate outcomes. 
Though methods and approach to data collection may vary from one field of discipline to the 
other, the emphasis has always been the same.  
Jansen, et al., (2005), observed that the use of guidelines in data collection enhances the 
quality of the research data. They found that a well-designed case record form and a 
handbook for standardized data collection are important in the training of data collectors; 
ensuring fastidious searching of the record; and eliminating many subjective choices from the 
data collectors. The guideline provides the data collectors a standard operating procedure for 
data collection activities.  
Though it was time-consuming, developing a data collection guideline was quite essential for 
this study and it provided the procedure that helped improve the correctness and quality of 
the data. 
Data collection started on the 3
rd
 of September 2012 and was concluded on the 31
st
 of 
October 2012. Within this period, a total of 575 folders were reviewed at both Frere and 
Cecelia Makiwane hospital taking 20 folders per day. This arrangement was done to avoid 
putting much pressure on the already over-stretched staff at the medical records. 237 folders 
were found to have met the inclusion criteria at both hospitals. Out of this lot, 31 were for the 
deceased and 206 for the surviving patients. Quite a reasonable number of folders were not 
found especially those for the deceased at both hospitals.  However, admission book showed 
that within the period under review, 68 CM patients died while on admission at both hospitals 
 
3.2.8 Variables of interest and tabulation of data: 
According to Manisha, Juthani-Mehta; Vincent, J Quagliarello, (2004), prognostic estimates 
can be based on three generic categories namely: Demographic and Clinical characteristics; 
Process of Care; and the Severity of Disease. Taking a clue from this submission, variables 
concerned with patients’ demographics, clinical characteristics and process of care were 
recorded. Data collection was done using the Case Record Form. The variables recorded in 
the CRF are tabulated as shown below: 
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Table 3.2 Patients Demographic Information 
                    DESCRIPTION       
                    
VARIABLES 
LEVELS OF  
 
VARIABLES 
NO OF  
OBS. 
DECEASED SURVIVED 
AGE 
RANGE =  62-13=49 
≤ 35 YEARS 137 (57.8%) 17 120 
>35 YEARS 100 (42.2%) 14 86 
GENDER FEMALES 132 (55.7%) 15 117 
MALES 105 (44.3%) 16 89 
RACE BLACKS 233 (98.3%) 30 203 
COLOUREDS 4       (1.7%) 1 3 
LOCALITY INFORMAL 144 (60.8%) 18 126 
TOWNSHIPS 66   (27.8%) 9 57 
SUBURBS 27   (11.4%) 4 23 
SOCIO-ECONOMIC 
STATUS 
UNEMPLOYED 207 (87.3%) 27 180 
EMPLOYED 30   (12.7%) 6 26 
SMOKING STATUS 
 
NON- SMOKER 192 (81.0%) 21 171 
SMOKER 45   (19.0%) 10 35 
LEVEL OF  
CONSCIOUSNESS 
LOW 51   (21.5%) 22 29 
NORMAL 186 (78.5%) 9 177 
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Figure 3.1                            Plot of Patients' Demographic Data 
Died 
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Table 3.3: Patients Pre-Existing Health Condition 
                     DESCRIPTION 
 
VARIABLES 
LEVELS  NO. OF OBS DECEASED SURVIVED 
DIABETIC NO 6       (2.5%) 0 6 
YES 3       (1.3%) 0 3 
UNKNOWN 228 (96.2%) 31 197 
T.B NO 99   (41.8%) 1 98 
PREVIOUS 40   (16.9%) 5 35 
CURRENT 98   (41.3%) 25 73 
HIV STATUS NEGATIVE 2       (0.8%) 0 2 
POSITIVE 218 (92.0%) 28 190 
UNKNOWN 17     (7.2%) 3 14 
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        Figure 3.2 :                Plot of Patients' Pre-existing Health Condition       
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Table 3.4: Patient In-Hospital Care Data 
              DESCRIPTIONS           
VARIABLES 
LEVELS OF  NO.OF 
OBS. 
% OF 
OBS. 
DECEASED SURVIVED 
    TREATMENT  
     REGIMEN 
AMPHOTERICIN 
B 
174 73.4% 18 156 
FLUCONAZOLE 31 13.1% 4 27 
BOTH 27 11.4% 5 22 
NOAM_FL 5 2.1% 4 1 
 SYSTOLIC BP 
RANGE= 217-79= 138 
< 105 57 24.1% 10 47 
105-135 123 51.9% 13 110 
>135 55 23.2% 8 47 
MISSING 
VALUES 
2 0.8% 0 2 
DIASTOLIC BP < 60 22 9.3% 5 17 
> 90 35 14.8% 6 29 
NORMAL 178 75.1% 20 158 
MISSING 
VALUES 
2 0.8% 0 2 
DURATION ON ADMISSION 1-7 DAYS 36 15.2% 19 17 
8-14 DAYS 59 24.9% 3 56 
15-21 DAYS 94 39.7% 5 89 
  ≥ 22 DAYS 48 20.2% 4 44 
ON ART BEFORE ADMISSION NO 140 59.1% 22 118 
YES 97 40.9% 9 88 
TRT ADHERENCE NO 155 65.4% 27 128 
YES 82 34.6% 4 78 
WAS AmB STOPPED BEFORE 14 
DAYS? 
NO 125 52.7% 4 121 
YES 76 32.1% 19 57 
NOT USED 36 15.2% 8 28 
DURATION ON AmB      
1- 7 DAYS 64 27.0% 21 43 
8-13 DAYS 46 19.4% 5 41 
UP TO 14 DAYS 125 52.7% 4 121 
NO RECORDS 2 0.8% 1 1 
CD4 COUNT ≤50 109 46% 11 98 
 >50 96 40.5% 13 83 
 UNKNOWN 32 13.5% 7 25 
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Table 3.5: Presenting Symptoms in the Study  
                    DESCRIPTIONS                
VARIABLES 
NO. OF PATIENTS  PERCENTAGE OF PATIENTS  
HEADACHE 223 94.1% 
NECK-STIFFNESS 122 51.5% 
VOMITING 120 50.6% 
CONFUSION 65 27.4% 
PHOTOPHOBIA 59 24.89% 
FEVER 47 19.8% 
PAINS 32 13.5% 
BODY WEAKNESS 23 9.7% 
FITS 18 7.5% 
DIZZINESS 14 5.9% 
OTHERS 82 34.6% 
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3.3 Missing Data: 
How best to deal with missing data should be a decision that will be taken from time to time 
in every study. Though there have been several proposals on how to deal with missing data, 
the procedure depends on the nature of the missing data and the extent of the missingness. 
 
3.3.1 Dealing with missing data:  
Complete Case Analysis: This technique involves eliminating observations with missing 
entries from the data and performing analysis with the remaining data. One of the 
shortcomings of this technique is the biasedness that occurs when units with missing values 
differ systematically from the completely observed cases. Also, in situations where many 
independent variables are involved and missingness is spread across these variables and 
observations, complete-case analysis will lead to a serious reduction in the data sample size. 
In Missing Completely At Random (MCAR) cases, the complete case analysis can lead to an 
unbiased estimate and a loss of power. In Missing At Random (MAR) cases, it can lead to 
biased estimates. 
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Mean Substitution: Mean substitution implies using the variable mean as a substitute for the 
missing entries in that variable. Though quite easy to carry out, it has so many inadequacies. 
Firstly, mean substitution ignores the category or grouping for the observation in assigning 
values to the missing entries in that variable. A Mean substitution in this data set for 
“duration of hospital admission” will allocate values without taking note of other variables 
like gender and locality which have various levels under examination. Such ignorance can 
bias the outcome of the analysis especially in the presence of several missing values in the 
variable “duration of admission”. Secondly, mean substitution will decrease the actual 
standard error  Se  of the regression coefficient while the regression coefficients   remain 
the same. The reason is that mean substitution increases the sample size n  which is the 
denominator of the standard error of the regression coefficient without adding new 
information to the dataset. Also, the overall mean remains unchanged even after the 
substitution. 
Regression substitution: Regression substitution provides remedy for the first inadequacy in 
the mean substitution. Its imputed values are based on other information about the 
observation. For the duration of hospital admission example above, regression imputation 
will take note of gender and locality in assigning value to missing entries in ‘duration of 
hospital admission’. This will to an extent, help maintain the integrity of the data. However, it 
fails to address the problem of error variance. Like mean substitution, it increases the sample 
size of the data without adding any new information resulting in a reduction in the standard 
error. Regression substitution can be improved by adding some bits of random error to each 
substitution.  
Imputation based on logical rules: This involves imputing missing entries using logical rules. 
It does not rely on any particular assumption but require a good knowledge of the missing 
data mechanism. This technique was used to address missingness among categorical entries 
in this study. Taking the “on_art” (i.e. whether the patient was on anti-retroviral treatment 
prior to CM episode) categorical variable and a situation where a patient’s hiv_st (HIV status) 
reads unknown or negative for instance. Logical rules will require that the answer for ‘on_art’ 
be ‘NO’ since someone who is HIV negative or with unknown HIV status cannot be enrolled 
for Anti-Retroviral Treatment.  
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Missingness among nominal categorical predictors: This technique involves adding an extra 
category for the nominal categorical predictor variable indicating missingness. An example 
will be to create another category for ‘hiv_st’ variable for ‘no response’ to take care of people 
who were not willing to disclose their HIV status in a survey; rather than treating them as 
missing data or ‘unknown’ category. However, this technique can produce biased estimates. 
Multiple Imputations: Although multiple Imputations (MI) technique for missing data has 
been seen as appropriate, its applications has been found to be rare mainly due its difficult-to-
use algorithm. It substitutes random data for the missing values by adding an error 
component drawn from the residual distribution








YY
to the predicted value. (David, 
2009). To avoid the technique under-estimating the standard error, the imputation is repeated 
several times generating multiple sets of new data whose coefficients vary from set to set. 
The use of this technique does not diminish the sample size of the data.  
 
Imputations based on logical rules were employed in the study data.  
Locality and Race: Related variables were used to predict the others where there is 
missingness. The apartheid system that existed in South Africa brought in racial demarcations 
that compelled various race groups to live exclusively from the other groups. Although the 
law is no longer in force today, however the demarcations are still in existence. This situation 
was helpful in determining either the race of a patient from the recorded address with an 
appreciable level of certainty. For Example, a patient with locality recorded as ‘Duncan 
village’ no doubt, will be of the black race while a patient with locality recorded as 
pefferville will definitely be of the coloured race.  
Level of consciousness: Level of consciousness is either normal or low. Low level of 
consciousness implies a less than 15 Glasgow coma score or any report of abnormal mental 
status in the patient’s folder. A normal level of consciousness implies a Glasgow coma score 
of 15 or the absence of any report of abnormal mental status for the patient on arrival at the 
hospital. 
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Table 3.6 Glasgow Coma Score Table 
EYE OPENING (E) 
4 Opens Eyes Spontaneously 
3 Opens Eyes to Voice 
2 Opens Eyes to Pain 
1 No Eye Opening 
BEST MOTOR RESPONSE (M) 
6 Obeys Command 
5 Localizes to Pain 
4 Withdraws to Pain 
3 Abnormal Flexor Response 
2 Abnormal Extensor Response 
1 No Movement 
BEST VERBAL RESPONSE (V) 
5 Appropriate and Oriented 
4 Confused Conversation 
3 Inappropriate Words 
 
HIV Status (hiv_st), On Art before CM (on_art) and Adherence to Treatment (Trt_adh): 
These three variables were used together to reconcile missing values among themselves. A 
missing value in hiv_st with an entry of ‘yes’ for the on_art variable implies that hiv_st will 
definitely be ‘positive’ for that patient. A search through the folders reveals whether a patient 
has been adhering to treatment instruction. Comments depicting a default in ART or 
inconsistency in collecting fluconazole maintenance therapy from the ARV pharmacy are 
clear indications of non-adherence to treatment. However, in some cases, comments on 
adherence to treatment are found missing in the folders. To identify this missing value, the 
patient hiv_st is also looked at. A patient whose hiv_st is unknown is taken as not adhering 
to treatment instruction. The reason been that the government and the Department of Health 
have consistently called on all people to ensure they get tested for HIV and to access  
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treatment where the outcome is positive. Hence people who have not heeded to this call were 
viewed as not adhering to treatment instructions as far as this study is concerned.  
 
3.4 Ethics 
3.4.1 Ethical Review: 
Prior to the commencement of this study, the research protocol was reviewed for compliance 
with ethical standards by the Faculty of Science and Agriculture Research Ethics Committee 
of the University of Fort Hare and further by the University of Fort Hare Research and Ethics 
Committee. Ethical Clearance Certificate for this study was granted by the latter on the 16
th
 
of July 2012. 
At the East London Hospital Complex, the study proposal and protocol was again reviewed 
by the East London Hospital Complex Ethics Committee. Clearance was issued for the study 
to proceed on the 20
th
 of August 2012. The study was finally approved to be carried out at the 
Hospital Complex by Dr J. Thomas - the Acting Clinical Director of the Hospital Complex on 
21
st
 August 2012.  
3.4.2 Ethical Considerations: 
Ethical considerations for this study were made in line with the Belmont Report of 1979 on 
the ethical principles and guidelines for the protection of human subjects of research 
(Belmont Report, 1979), the Helsinki declarations of 1964 on ethical principles for medical 
research involving human subjects (Helsinki Declaration, 1964) and other available 
guidelines in South Africa. (Department of Health, 2006). 
Competence: Every aspect of this research was handled by professionally trained 
people. Data analysis was done at the University of Fort Hare Statistical Laboratory 
by the researcher.  
Integrity: Honesty and fairness were upheld in this study. The limitations, weakness 
and strength of this study were clearly spelt out in this dissertation. Data quality was 
upheld and used as obtained, unless in situations where missingness has to be dealt 
with. In such cases, the procedure for imputing missing data as described above was 
followed. 
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Confidentiality: Patients’ confidentiality was ensured through the use of codes in 
place of the patient’s name in our CRF forms and the use of password-protected 
database for the storage of collected data.  
Informed Consent: A waiver of informed consent according to Lyn, (2009) was 
incorporated into the study proposal on the following grounds:  
 The study made use of patients’ folders and did not come in contact with the 
patients’. 
 Many of these patients’ have died and their relatives cannot be traced. 
 For some other patients, their residential addresses have changed from the one 
recorded at the time of admission on the folders. 
 Where contact numbers were recorded in the folder, they were no longer in 
use. 
In summary, getting in contact with all the owners of these folders will be an up-hill task that 
cannot be achieved, hence the need for a waiver of informed consent.  
Demarcation of Roles: Clear description of roles was spelt out for every member of 
the team and the contributors. In doing this, attention was given to area of 
professional specialization.  
Feedbacks: Results from this research will be communicated to the East London 
Hospital Complex, the University of Fort Hare and to the public via publications in 
journals and radio talks especially local radio stations like the Mdantsane FM. 
Hazards: There were no clinical or non clinical dangers envisaged in this study and 
even until the end of the study, none was found. 
Payments: With the exception of the data collectors/ capturers, no one was paid for 
any role played in the course of this study. 
Ethics of Justice, Fairness and Objectivity: There were no discriminations among the 
folders selected for this research. Folders for all races, age groups, gender and social 
classes were considered based on the study’s inclusion criteria.  
Benefit: The study identified variables that are significantly associated with patients’ 
survival or mortality which will be helpful in improving the prognosis of the disease 
and treatment as well.  
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3.5 Limitations/Challenges: 
The major challenge which this study had to contend with came as a result of manpower 
shortage at the Patient Administration in particular; and the shortage of medical professionals 
in South Africa in general. This study was originally intended to be a longitudinal prospective 
study but ended up a cross-sectional retrospective study due to shortage of medical 
professionals in South Africa; time constraint and limited resources. The data collection took 
longer period of time and resources due to the agreement to issue out 20 folders each day to 
the data collectors to avoid impeding on the normal routine of the medical record staff. At the 
CMH, the staff schedules were tighter and created a situation where less than 20 folders were 
issued per day. For some other days, no folders were issued at all.  However, patience and 
perseverance were the attributes that saw this study through.  
Another challenge was the unavailability of most folders requested from the medical records 
office as they could not be found especially for the deceased patients. 
Finally adequate precaution should be taken in generalizing the findings of this study to other 
geographical areas outside the jurisdiction of the East London Hospital Complex. 
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     CHAPTER FOUR 
4.0 DATA ANALYSIS AND STUDY RESULTS  
In this chapter, variables were examined for their relevance in a univariable regression to 
determine their strength in predicting CM outcome. Predictor variables that were significant 
in the univariable analysis were included in the multivariable logistic regression analysis for 
further examination of their relevance. It also presents the prognostic model for survival and 
mortality outcomes.  
 
4.1 Univariable Logistic Data Analyses: 
In this chapter, the association between each explanatory variable is tested at a time with the 
outcome with the aim of identifying variables for the multivariable analysis. It helps in 
preventing variables that are not significantly associated with the response variable from 
participating in the multivariable analysis. 
For the categorical predictor variables, appropriate care was taken in the choice of the 
reference variable in line with the category of the response variable been examined. 
All variables were tested at a significance level α = 0.05. The null and alternative hypotheses 
for these tests were formulated as follows: 
H0: The effect of the predictor variable on CM outcome = 0 
H1: The effect of the predictor variable on CM outcome ≠ 0 
 
The decision will be made in favour of H1 if the p-value ≤ α and in favour of H0 otherwise. 
 
4.1.1 Univariable Analysis of Patients’ Demographics. 
In this section, the demographics of the patients were examined to ascertain their prognostic 
effects on the outcome (i.e. mortality). The patients’ age, gender, race, locality, socio-
economic status, social habits and level of consciousness were considered.    
 
 
 
 
 
 
      35                     
Table 4.1: Result of Patients’ Demographics in relation to mortality  
                    DESCRIPTION      
VARIABLES 
    LEVELS  
 
ODDS 
RATIO 
    
C.I FOR ODDS   
    RATIO 
   P-VALUES 
 
AGE >35 YEARS 1.149 (0.538 - 2.456) 0.7199 
GENDER FEMALES 0.713 (0.335 - 1.519) 0.3810 
RACE BLACKS 2.256 (0.227 - 22.395) 0.4873 
LOCALITY INFORMAL 0.905 (0.383 - 2.136) 0.6785 
SUBURBS 1.152 (0.321- 4.127) 0.7443 
SOCIO-ECONOMIC STATUS EMPLOYED 1.026 (0.332 - 3.168) 0.9647 
SMOKING STATUS NON-SMOKER 0.430 (0.186 – 0.992) 0.0478 
LEVEL OF CONSCIOUSNESS LOW 14.920 (6.225 - 35.585) <0.0001 
 
     Analysis of Maximum Likelihood Estimates for Smoking 
       Standard           Wald 
            Parameter              DF     Estimate        Error      Chi-Square     Pr > ChiSq 
  Intercept               1      -1.6749       0.2133        61.6454         <.0001 
            Smok_st   non-smok      1      -0.4222       0.2133         3.9167         0.0478 
 
     Odds Ratio Estimates 
      Point                 95% Wald 
                  Effect                            Estimate       Confidence Limits 
   Smok_st non-smok vs smoker         0.430        0.186       0.992 
 
No association was established between the demographic variables and CM outcome as can 
be seen from Table 4.1. However, Smoking and Low Level of consciousness 
 0001.0,0478.0  pandp  were found significantly associated to CM outcome. This 
implies that smoking and low level of consciousness (<15 on a Glasgow coma score) are 
significant predictors of mortality. It was found from the odds ratio estimate that the chances 
of  patients who were smoking up to the time of their hospital admission dying is about two 
times higher compared to those who have not smoked before. This result is in line with the 
findings of Canessa, J; Cabrera, D; Eskenazi, J; Samalvides, F; (2011)  on Glasgow at 
admission (OR = 4.55 (1.61 – 12.20), p = 0.01).  
  Analysis of Maximum Likelihood Estimates for Level of Consciousness 
      Standard           Wald 
            Parameter            DF     Estimate        Error      Chi-Square     Pr > ChiSq 
 Intercept             1      -1.6276       0.2218        53.8703         <.0001 
            Lev_con   low         1       1.3513       0.2218        37.1352         <.0001 
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Though the demographic variables are not associated with CM outcome, however from Table 
4.1 odds ratio estimate, it is clear those patients >35 years of age, males and blacks are 
associated with mortality though insignificantly.  
 
4.1.2 Univariable Analysis of patients’ Pre-Existing Health Condition. 
This section investigates the effect of pre-existing immuno-depressant ailments or co-
infections as a prognostic factor in determining the final in-hospital outcome. Diabetes, 
Tuberculosis and HIV status were considered in this section. 
 
Table 4.2: Result of Pre-Existing Health Condition in relation to Mortality 
          DESCRIPTION                 
VARIABLES 
LEVELS  ODDS RATIO C.I. FOR ODDS RATIO P-VALUES 
 
TB CURRENT 33.551 (4.45 – 253.25) 0.0007 
PREVIOUS 13.996 (1.58 – 123.95) 0.0177 
NO 
NO 0.030 (0.004 – 0.225) 0.0007 
PREVIOUS 0.417 (0.147 – 1.182) 0.0998 
CURRENT 
HIV STATUS NEGATIVE 
POSITIVE 0.748 (0.035 – 15.982) 0.8526 
UNKNOWN 1.207 (0.047 – 31.220) 0.9098 
       
                     Analysis of Maximum Likelihood Estimates for Tuberculosis in relation to Survival 
       Standard           Wald 
            Parameter              DF     Estimate        Error      Chi-Square     Pr > ChiSq 
  Intercept               1       4.5846       1.0049        20.8132         <.0001 
             tb        current       1      -3.5131       1.0313        11.6038         0.0007 
             tb        previous     1      -2.6387       1.1129         5.6223         0.0177 
 
In the result above, the outcome event examined is “survived”. The coefficients for previous 
and current cases of tb were negative indicating that the two are negatively associated with 
survival of the patient. However, the significance of tb_prev was found doubtful and had to 
be investigated further. The estimated correlation matrix was outputted as shown below to 
examine the correlation between tb_curr and tb_prev  88.0 , and they were found to be 
strongly correlated.  
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Controlling for tb_curr, the association of tb_prev and tb_no on survival were again verified. 
Their outputted correlation matrix showed a very weak relationship. The regression 
coefficient for tb_prev as shown below is 0.8743 for Outcome=Survival implying that the 
negative relationship with Outcome=Survival when controlling for another variable had been 
lost. This implies that tb_prev may be a co-founder in the model.  
                                               Estimated Correlation Matrix 
  Parameter         Intercept       tb current       tb previous 
   Intercept           1.0000         -0.9744          -0.9030 
                       Tb current          -0.9744          1.0000            0.8799 
                       Tb previous         -0.9030          0.8799            1.0000 
                                                                                                                    
                                         Analysis of Maximum Likelihood Estimates for Tuberculosis 
        Standard           Wald 
            Parameter              DF     Estimate        Error      Chi-Square     Pr > ChiSq 
  Intercept               1       1.0716       0.2317        21.3840         <.0001 
            Tb        no             1       3.5131       1.0313        11.6038         0.0007 
            Tb        previous      1       0.8743       0.5313         2.7082         0.0998 
 
 
                                             Estimated Correlation Matrix 
 Parameter         Intercept             tb no       tb previous 
  Intercept           1.0000        -0.2247           -0.4362 
         Tb no               -0.2247         1.0000             0.0980 
     Tb previous         -0.4362         0.0980             1.0000 
                                                                          
The three patients with cases of diabetes survived indicating that Diabetes may not be a threat 
to the survival of CM patients. Again, though 92% of CM patients are HIV positive, HIV 
status was found not to be significantly associated with CM outcome  7396.0p . HIV+ 
status, though a risk factor for CM is not an outcome predictor of CM. 
 
4.1.3 Univariable Analysis of In-hospital Care data.  
This section considers the variables that are measured while the patient is on admission at the 
hospital. It verifies the relationship between each of the variables and the response variable. 
Only the significant variables were used in the multivariable regression analysis. 
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Table 4.3: Result of In-hospital Care data in relation to Patients’ mortality. 
                                 
Univariable analysis result found the entire regimen (AmBd; OR=34.65, CI=3.672-     
327.070, p=0.0020; BOTH OR=17.594, CI=1.602-193.284 p=0.0190; F_azole OR=26.991, 
CI=2.377-306.493 p=0.0079) for CM treatment effective when compared to “not using any 
regimen” Noam_fl.  
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    DESCRIPTIONS       
VARIABLES 
LEVELS  ODDS 
RATIO EST 
C.I. FOR         
ODDS RATIO 
         P-VALUES 
TRT_REG FLUCONAZOLE 1.28 (0.403 – 4.087) 0.6722 
BOTH 1.97 (0.664 – 5.84) 0.2215 
NOAM_FL 34.67 (3.67 – 327.24) 0.0020 
AMB IS THE REFERENCE 
 SYSTOLIC BP < 105 1.833 (0.751- 4.473) 0.1830 
105-135 IS THE REFERENCE  
>135 1.466 (0.570 - 3.770) 0.4268 
DIASTOLIC BP < 60 2.324 (0.773 - 6.982) 0.1331 
> 90 1.634 (0.605 - 4.419) 0.3329 
NORMAL IS THE REFERENCE   
DOF_ADM 1-7 DAYS 12.293 (3.648 - 41.425) < .0001 
8-14 DAYS 0.589 (0.125 - 2.771) 0.0622 
15-21 DAYS 0.618 (0.158 - 2.416) 0.0350 
≥ 22 DAYS IS THE REFERENCE 
ON_ART BEFORE 
ADMISSION 
NO 1.823 (0.8 - 4.152) 0.1528 
YES IS THE REFERENCE 
TRT_ADH NO 4.113 (1.387 - 12.199) 0.0108 
YES IS THE REFERENCE  
AmB_STP 
BEFORE 14 DAYS 
NO IS THE REFERENCE 
YES 10.083 (3.279 - 31.002) < .0001 
DON_AmB     
1- 7 DAYS 7.107 (2.164 - 23.335) 0.0012 
8-13 DAYS IS THE REFERENCE 
UP TO 14 DAYS 0.271 (0.069 - 1.058) 0.0603 
CD_4 COUNT ≤50 0.717 (0.305 - 1.684) 0.4447 
            >50 COUNTS IS THE REFRENCE 
UNKNOWN 1.788 (0.643 - 4.967) 0.2652 
   Analysis of Maximum Likelihood Estimates for Treatment Regimen 
       Standard           Wald 
            Parameter             DF     Estimate        Error      Chi-Square     Pr > ChiSq
 Intercept               1      -1.3859       1.1179         1.5370         0.2151 
            Trt_reg   ambd         1       3.5454       1.1453         9.5830         0.0020 
            Trt_reg   both         1       2.8676       1.2228         5.4995         0.0190 
            trt_reg   f_azole      1       3.2955       1.2397         7.0669         0.0079 
 
     Odds Ratio Estimates 
        Point               95% Wald 
                   Effect                          Estimate       Confidence Limits 
  Trt_reg ambd    vs noam_fl       34.655        3.672     327.070 
            Trt_reg both    vs noam_fl       17.594        1.602     193.284 
            trt_reg f_azole vs noam_fl       26.991        2.377     306.493 
 
A combination of both therapies was found to be less effective compared to Amphotericin B 
or Fluconazole monotherapy. However, Amphotericin B was found the most effective 
compared to fluconazole monotherapy and a combination of both. Patients who received 
AmBd are likely to survive 34 times more, compared to patients that received none of the 
regimen.  
When controlling for AmBd, it was found that noam_fl (OR=34.666, CI=3.672-327.243, p= 
0.0020) was significantly associated with mortality.    
   Analysis of Maximum Likelihood Estimates for Treatment Regimen 
       Standard          Wald 
             Parameter             DF     Estimate        Error      Chi-Square     Pr > ChiSq 
  Intercept              1      -2.1595       0.2489        75.2572         <.0001 
            Trt_reg   both         1       0.6779       0.5545         1.4948         0.2215 
            trt_reg   f_azole      1       0.2499       0.5908         0.1790         0.6722 
            trt_reg   noam_fl      1       3.5458       1.1454         9.5830         0.0020 
 
    Odds Ratio Estimates For Treatment Regimen 
        Point                     95% Wald 
                   Effect                          Estimate        Confidence Limits 
 Trt_reg both    vs ambd            1.970         0.664         5.839 
           trt_reg f_azole vs ambd            1.284         0.403         4.087 
          trt_reg noam_fl vs ambd           34.666         3.672     327.243 
                                           
                                                 Estimated Correlation Matrix 
      trt_reg           trt_reg               trt_ reg  
                Parameter            Intercept       both    f_azole             noam_fl 
    Intercept               1.0000       -0.4490       -0.4214        -0.2173 
                Trt_reg both          -0.4490        1.0000        0.1892          0.0976 
                trt_reg f_azole     -0.4214        0.1892        1.0000          0.0916 
                trt_reg noam_fl    -0.2173        0.0976        0.0916          1.0000 
                                                                         
The variables – Systolic and Diastolic blood pressures were found not to be significantly 
associated with CM outcome. This finding is contrary to the finding of Lightowler, J V J; 
Cooke, G S; Mutevedzi, P; Lessells, R J; Newell, M L; et al, (2010) where diastolic blood  
 
      40 
pressure <60 mmHg were obtained as follows: (aHR 2.37 95%C.I. 1.11–5.04, P = 0.025). It 
could be that the procedure employed by the East London Hospital Complex in managing 
patients’ blood pressures is effective.  
The duration of admission (Dofadm) was also examined for its association with mortality. It 
was found that day 1 to day 7 (p= <0.0001) is strongly associated with patient mortality while 
beyond the 7
th
 day of admission, Dofadm is associated with survival. This complies with the 
findings of Canessa, J; Cabrera, D; Eskenazi, J; Samalvides, F; (2011) that longer hospital 
stay was a protective factor against mortality. (OR = 0.80 (0.69 – 0.93, p = 0.005). Dofadm 
on its own is not a predictor of CM outcome but a surrogate for the uninterrupted treatment 
with an effective regimen (especially Ambd and Fluconazole) for this period of time. 
     
  Analysis of Maximum Likelihood Estimates for Duration on Hospital Admission 
       Standard           Wald 
 Parameter              DF     Estimate        Error      Chi-Square     Pr > ChiSq 
  Intercept               1      -2.3979       0.5222        21.0830         <.0001 
           Dofadm    1-7days       1       2.5091       0.6198        16.3865         <.0001 
           Dofadm 15-21day      1      -0.4813       0.6957         0.4787         0.4890 
           Dofadm    8-14days      1      -0.5288       0.7899         0.4483         0.5032 
 
     Odds Ratio Estimates 
      Point                 95% Wald 
                  Effect                           Estimate       Confidence Limits 
       Dofadm 1-7days vs >=22days      12.293          3.648      41.425 
                  Dofadm 15-21day vs >=22days       0.618          0.158       2.416 
                  Dofadm 8-14days vs >=22days       0.589          0.125       2.771 
                                           
         Analysis of Maximum Likelihood Estimates 
       Standard           Wald 
            Parameter              DF     Estimate        Error      Chi-Square     Pr > ChiSq 
  Intercept               1      -0.1112       0.3338         0.1109         0.7391 
            Dofadm 15-21day      1       2.9904       0.5681        27.7116         <.0001 
            Dofadm   8-14days      1       3.0379       0.6802        19.9481         <.0001 
            Dofadm   >=22days     1       2.5091       0.6198        16.3865         <.0001 
 
 
                                       Odds Ratio Estimates 
      Point           95% Wald 
                 Effect                           Estimate       Confidence Limits 
       Dofadm 15-21day vs 1-7days        19.893        6.534      60.566 
                  Dofadm 8-14days vs 1-7days        20.862        5.500      79.125 
                  Dofadm >=22days vs 1-7days       12.293        3.648      41.425 
 
Though in-hospital admission beyond the 7
th
 day is a protection against mortality, however 
the chance of survival decreases with increasing number of in-hospital admission days as can 
be seen from the odds estimates. 
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                                           Estimated Correlation Matrix 
       dofadm      dofadm      dofadm 
               Parameter            Intercept            15-21day         8-14days         ≥22days 
    Intercept                1.0000       -0.5877        -0.4908        -0.5386 
              dofadm15_21day    -0.5877           1.0000         0.2885         0.3165 
              dofadm8_14days  -0.4908           0.2885         1.0000         0.2644 
              dofadm__22days  -0.5386           0.3165         0.2644         1.0000 
 
Also looking at the correlation matrix, it is prominent that the correlations between the 
variables are weak- to- moderate which is tolerable among categorical predictors in a logistic 
regression as the VIF’s are likely to remain low. (Allison, 2012). 
                                           
       Analysis of Maximum Likelihood Estimates for Stopping AmBd Before the 14th Day 
       Standard          Wald 
            Parameter         DF     Estimate          Error     Chi-Square     Pr > ChiSq 
               Intercept          1      -3.4094       0.5082        45.0116         <.0001 
               Amb_stp   yes      1       2.2626       0.5541        16.6730         <.0001 
 
     Odds Ratio Estimates 
       Point                           95% Wald 
                        Effect                  Estimate        Confidence Limits 
  Amb_stp yes vs no          9.608             3.243      28.465 
 
Stopping the use of Amphotericin B in the treatment of a patient before the 14
th
 day 
(Amb_stp) was found significantly associated with mortality. Unfortunately, this study did 
not attempt to take a critical view at the likelihood of survival with increasing number of days 
of uninterrupted use of Amphotericin B. Although the variable Don_amb (i.e. the duration on 
Amphotericin B) was not structured to meet the challenge above, however it can be inferred 
from its result below that the longer the period of consistent in-hospital use of Amphotericin 
B on the patient, the lower the chances of death. 
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Table 4.4 Number of dead and Surviving Patients with respect to no. of days of receipt of           
       Amphotericin B. 
 No of Days No. that Survived No. that died Total no.     
     of Patients 
2 days 4 2 6 
3 days 2 2 4 
4 days 1 3 4 
5 days 1 4 5 
6 days 3 3 6 
7 days 4 2 6 
8 days 6 2 8 
9 days 3 1 4 
10 days 8 1 9 
11 days 6 1 7 
12 days 12 1 13 
13 days 5 0 5 
14 days 123 6 129 
Unknown 28 3 31 
 
                  
From the plot above, it can be seen that mortality increased with increasing number of days 
of consistent treatment with Amphotericin B and reached its peak on the 5
th
 day. Thereafter, 
it declined until the 14
th
 day. Though six patients died on the 14
th
 day, it does not imply an 
increase in mortality especially when the number of deaths on the 14
th
 day is compared to the 
129 patients that reached the 14
th
 day as well. The scenario can better be understood from the 
percentage plot below. It can then be said that beyond the 5
th
 day of consistent treatment with 
Amphotericin B, patients’ mortality decreased till the 14th day. 
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Figure 4.1 Plot of Mortality vs Days of Consistent 
Treatment with Amphotericin B 
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  Analysis of Maximum Likelihood Estimates for Duration on AmBd Therapy 
       Standard           Wald 
            Parameter              DF     Estimate        Error      Chi-Square     Pr > ChiSq 
  Intercept               1      -3.4094       0.5082        45.0116         <.0001 
           Don_amb 1-7days       1       2.6928       0.5737        22.0310         <.0001 
           Don_amb 8-13days     1       1.3053       0.6947         3.5302         0.0603 
           Don_amb unknown     1       3.4094       1.5027         5.1475         0.0233 
 
      Odds Ratio Estimates 
      Point                  95% Wald 
         Effect                            Estimate        Confidence Limits 
  Don_amb 1-7days vs 14days         14.772         4.799      45.476 
      Don_amb 8-13days vs 14days          3.689         0.945      14.396 
        Don_amb unknown vs 14days         30.248         1.591     575.231 
                                           
It was also found that not being on Anti-retroviral treatment )823.1,1528.0(  ORp  before 
CM infection was not a significant predictor of mortality. 
    
                               Analysis of Maximum Likelihood Estimates for Treatment Adherence 
       Standard           Wald 
               Parameter         DF     Estimate        Error      Chi-Square     Pr > ChiSq 
    Intercept          1      -2.2633       0.2773        66.5979         <.0001 
                Trt_adh   no       1       0.7071       0.2773          6.5005         0.0108 
 
     Odds Ratio Estimates 
      Point                95% Wald 
                        Effect                  Estimate       Confidence Limits 
  Trt_adh no vs yes         4.113        1.387      12.199 
 
Not adhering to treatment TRT_ADH (No) (p= 0.0108) was found to be significantly  
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Figure 4.2 Percentage Plot of Mortality vs Days of 
Consistent Treatment with AmBd 
associated with patient mortality. This resonates with the findings of Collett & Parrish, 
(2007) that emphasis should not be limited to the roll-out of medication but also on the 
quantification of sustained clinical benefits
 
having observed that most of the patients abscond 
from their treatment.  
A mean CD_4 count ≤50 has no significant association with mortality. Surprisingly, patients 
with CD_4 count as low as “one” survived implying that there may be other factors 
exercising stronger deterministic control over the treatment outcome than the mean CD_4 
count. Again it may be that the introduction of HAART has been effective in bridging that 
gap.  This result contradicts the result from Mohammed & Chandrasekhara, (2009) in which 
they found that CD4 count ≤ 50 is associated with poor prognosis. Their sample had a mean 
CD4 count of 60.27 ± 41.51 (range 4 - 192). 
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4.1.4 Univariable Analysis of Presenting Symptoms. 
 
In this section, presenting symptoms were all analyzed in a univariable logistic analysis. 
 
Table 4.5: Univariable Analysis of Presenting Symptoms in Relation to Patients’   
                  Mortality 
           DESCRIPTION                 
VARIABLES 
LEVELS OF 
VARIABLES 
ODDS 
ESTIMATES 
C.I. FOR ODDS 
ESTIMATES 
P-VALUES 
HEADACHE NO 0.495 (0.062 – 3.922) 0.5054 
YES    
NECK-STIFFNESS NO 0.856 (0.401 – 1.828) 0.6881 
YES    
VOMITING NO 1.109 (0.521-2.361) 0.7886 
YES    
CONFUSION NO 0.342 (0.158-0.741) 0.0065 
YES    
PHOTOPHOBIA NO 0.946 (0.399 – 2.245) 0.8998 
YES    
FEVER NO 0.826 (0.333 – 2.052) 0.6808 
YES    
PAINS NO 0.602 (0.226 – 1.606) 0.3105 
YES    
BODY WEAKNESS NO 0.498 (0.170 – 1.455) 0.2024 
YES    
FITS NO 0.193 (0.068 – 0.546) 0.0019 
YES    
DIZZINESS NO 0.897 (0.191 – 4.213) 0.8904 
YES    
   
Univariable analysis of presenting symptoms showed that confusion (OR=2.925, CI =1.350 
6.337, p = 0.0065) is significantly associated with CM outcome. Presence of confusion 
(confusion yes) is associated with mortality while absence of confusion (confusion no) is 
significantly associated with survival. CM patients that had Confusion as a presenting 
symptom is about 3 times likely to die than those that did not.                            
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   Analysis of Maximum Likelihood Estimates for Confusion 
      Standard           Wald 
              Parameter         DF     Estimate        Error      Chi-Square     Pr > ChiSq  
 Intercept          1      -2.2773       0.2625        75.2565            <.0001 
             Confusion yes      1       1.0733       0.3944         7.4048            0.0065 
 
     Odds Ratio Estimates 
        Point                 95% Wald 
                       Effect                   Estimate        Confidence Limits 
             Confusion yes vs no           2.925          1.350       6.337 
 
Also Fits (p = 0.0019) was found to be significantly associated with CM outcome. CM 
patients presented with fits as a symptom are about 2 times likely to die compared to those 
that did not.                               
    Analysis of Maximum Likelihood Estimates for Fits 
       Standard          Wald 
               Parameter         DF     Estimate        Error     Chi-Square     Pr > ChiSq 
  Intercept          1      -1.2734       0.2648        23.1205         <.0001 
               Fits (no)       1      -0.8215       0.2648         9.6216         0.0019 
 
Contrary to findings in many publications that Headache (H_ache) is significantly associated 
with survival, the univariable analysis of headache in this study revealed that headache is not 
significantly associated with patient survival. The data for headache is also presented below 
for clarity. 
  
    Obs     h_ache     outcome      count 
    1       yes        died           30 
                                   2       yes        survived      193 
                                   3       no         died            1 
                                   4       no         survived       13     
 
The data showed that headache was a presenting symptom in 223 patients (representing 
94.1% of the patients) out of the 237 patients whose cases were reviewed and used in this 
study.             
                                        Analysis of Maximum Likelihood Estimates for mortality 
      Standard           Wald 
             Parameter         DF     Estimate        Error      Chi-Square     Pr > ChiSq 
  Intercept          1      -2.2132       0.5281        17.5659         <.0001 
             H_ache    no       1      -0.3517       0.5281         0.4436         0.5054 
 
From the odds ratio output, patients without headache are less likely to die compared to those 
presenting with headache. Also, the coefficient of headache in the model is negative when 
mortality is considered implying that not having headache is not associated with mortality. 
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    Odds Ratio Estimates 
     Point            95% Wald 
                      Effect                 Estimate        Confidence Limits 
     H_ache no vs yes        0.495         0.062       3.922 
 
   
4.2 Multivariable Logistic Regression Analysis of Predictors: 
This section tests the associations of variables with the outcome in a multivariable logistic 
regression while taking the confounders and other variables into account. 
 It allows for the establishment of a relationship between a binary response variable and a 
group of predictor variables. It models the logit-transformed probability as a linear 
relationship with the predictor variables. (UCLA, 2013). The justification for the logistic 
regression has earlier been dealt with in this study. This relationship will be examined in a 
multivariable logistic regression model using the SAS version 9.1.3 and NCSS 2007 version 
as we can see below. 
4.2.1 Model selection:  
This process can be performed using any of the three procedures namely: Forward Selection, 
Backward Elimination and Stepwise procedures. For this study, the hierarchical Forward 
selection procedure was used. 
 
Model Selection for Mortality: 
MODEL FITS|TRT_ADH|SMOKER|TB|LEV_CON|TRT_REG 
 
 
                                                   Subset Selection Summary Section for Mortality 
 No. No. Log R-Squared R-Squared 
 Terms X's Likelihood Value Change 
 1 1 -91.93416 0.000 0.000 
 2 2 -70.90397 0.313 0.313 
 3 4 -55.5774 0.542 0.228 
 4 5 -51.8492 0.597 0.056 
 5 6 -49.21831 0.636 0.039 
 6 7 -46.83302 0.672 0.036 
 7 10 -44.13824 0.712 0.040 
  
In 1000 iterations which the model was programmed for, Level of consciousness was the first 
variable to be selected with a log likelihood estimate of 70.90. Tb, Trt_adh, Fits, Smoker and Trt_reg  
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were other variables selected into the model with a final log likelihood of 44.13824. The addition of 
Conf to the model produced no reasonable effect. However, it is important to state that Conf is 
strongly associated with Lev_con and is strongly significant in the model in the absence of Lev_con. 
Leaving the two in the model may bias the result. 
                                          Subset Selection Detail Section for Mortality 
  No. of No. of Log Term Term 
Step Action Terms X's Likelihood Entered Removed 
1 Add 1 1 -91.93416 Intercept  
2 Add 2 2 -70.90397 LEV_CON  
3 Add 3 4 -55.5774 TB  
4 Add 4 5 -51.8492 TRT_ADH  
5 Add 5 6 -49.21831 FITS  
6 Add 6 7 -46.83302 SMOKER  
7 Add 7 10 -44.13824 TRT_REG  
 
 From the subset selection detail section, lowered Level of consciousness influences patients’ 
mortality more than all other variables in the model. It is been followed by Current cases of 
Tuberculosis, non-adherence to treatment, presence of fits and lastly smoking.   
 
  Parameter Significance Tests Section (Reference Group: OUTCOM = SURVIVAL) 
 Regression  Wald Wald Odds 
 Coefficient Standard Z-Value Prob Ratio 
Parameter (B or Beta) Error (Beta=0) Level Exp(B) 
B0: Intercept -1.463776 0.697 -2.1 0.036 0.23 
B1: (FITS | yes - no) 
 0.9529916 0.400 2.4 0.017 2.59 
B2: (LEV_CON | low - nor) 
 1.674743 0.320 5.2 0.000 5.34 
B3: (SMOKER | yes - no) 
 0.7970119 0.343 2.3 0.020 2.22 
B4: (TB | no - prev) 
 -3.364215 1.051 -3.2 0.001 0.03 
B5: (TB | current - prev) 
 2.219321 0.613 3.6 0.000 9.20 
B6: (TRT_ADH | no - yes) 
 0.8650325 0.368 2.3 0.019 2.38 
B7: (TRT_REG | both - ambd) 
 -0.1242402 0.655 -0.2 0.850 0.88 
B8: (TRT_REG | nu - ambd) 
 0.7403251 1.195 0.6 0.536 2.10 
B9: (TRT_REG | fluco - ambd) 
 0.4962576 0.751 0.7 0.509 1.64 
 
From the parameter significance section, presence of fits, lowered level of consciousness (<15 
Glasgow coma score), smoking, current cases of tuberculosis and not adhering to treatment were all 
significantly associated with CM mortality. Holding other variables constant, patients with lowered 
level of consciousness are more than 5 times likely to die than patients with normal consciousness.  
Patients having any of Fits are twice at risk of dying than patients not presented with the symptom. 
Patients who either smoke or fail to adhere to treatment put themselves twice at risk of dying  
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compared to other patients. Finally, patients with current cases of tb are 9 times as likely to die 
compared to those with previous cases of tb.  
 
                        Odds Ratios Section (Reference Group: OUTCOM = SURVIVAL) 
 Regression Odds Lower 95% Upper 95% 
 Coefficient Ratio Confidence Confidence 
Parameter (B or Beta) Exp(B) Limit Limit 
B0: Intercept -1.463776 0.23 0.06 0.91  
B1: (FITS | yes - no) 
 0.9529916 2.59 1.18 5.68  
B2: (LEV_CON | low - nor) 
 1.674743 5.34 2.85 9.99  
B3: (SMOKER | yes - no) 
 0.7970119 2.22 1.13 4.34  
B4: (TB | no - prev) 
 -3.364215 0.03 0.00 0.27  
B5: (TB | current - prev) 
 2.219321 9.20 2.77 30.57  
B6: (TRT_ADH | no - yes) 
 0.8650325 2.38 1.15 4.89  
B7: (TRT_REG | both - ambd) 
 -0.1242402 0.88 0.24 3.19  
B8: (TRT_REG | nu - ambd) 
 0.7403251 2.10 0.20 21.83  
B9: (TRT_REG | fluco - ambd) 
   0.4962576           1.64          0.38         7.16               
 
 
  
Estimated Logistic Regression Model for Mortality 






 )(1
)(
mortalityp
mortalityp
Log = -1.46 + 0.95*FITS (yes) + 1.67*LEV_CON (low) + 0.80*SMOKER (yes) +  
                                                  2.22*TB (current) + 0.87*TRT_ADH (no) 
 
  
Note that each model estimates B for a specific group, where Logit(Y) = XB. To calculate a 
probability, transform the logit using Prob(Y<>group) = 1/(1+Exp(-XB)) or Prob(Y=group)  
= Exp(-XB)/(1+Exp(-XB)). 
                        Classification Table 
 Estimated 
Actual 0 1 Total 
0 21 10 31 
1 6 200 206 
Total 27 210 237 
 
Percent correctly classified = 93.2% 
 
 ROC Section for Value 0 
Prob N(1|1) N(1|0) N(0|1) N(0|0) Sensitivity Specificity Sensitivity
 Proportion  
Cutoff A B C D A/(A+C) D/(B+D) +Specificity Correct  
0.050 31 62 0 144 1.000 0.699 1.699 0.738  
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The Receiver Operating Characteristic (ROC) curve is the plot of the true positive rate against the 
false positive rate for the different possible cut-points or rather, the plot of 1-specifity against 
sensitivity in a diagnostic test. It provides a quantitative summary of the strength of association 
between the underlying test statistic and the response variable. The plot below shows the curve very 
close to the y-axis indicating a stronger association between the underlying test statistic and the 
response variable. 
                                            
The area under the curve measures discrimination that is, the ability of the test to correctly 
classify both the dying and surviving patients. Values close to 1 indicate good predictive 
power while a value of 1 implies a perfect predictive power. The value for the area under the 
curve c = 0.942 (for mortality model) is an indication that the model classified the 
observations well. 
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          AREA UNDER THE CURVE = 0.942 
Model Selection for Survival: 
MODEL FITS|TRT_ADH|SMOKER|TB|LEV_CON|TRT_REG 
 
    
                                                   Subset Selection Detail Section for Survival 
 
  No. of No. of Log Term Term 
 Step Action Terms X's Likelihood Entered Removed 
 1 Add 1 1 -91.93416 Intercept 
 2 Add 2 2 -70.90397 LEV_CON  
 3 Add 3 4 -55.5774 TB  
 4 Add 4 5 -51.8492 TRT_ADH  
 5 Add 5 6 -49.21831 FITS  
 6 Add 6 7 -46.83302 SMOKER  
 7 Add 7 10 -44.13824 TRT_REG   
Logistic regression forward hierarchical selection showed that having a normal level of 
consciousness is the most effective prognostic factor among all the variables considered. Others 
include not having had any case of Tuberculosis before, adhering to treatment instruction, no traces 
of fits, not having smoked before and using Amphotericin B regimen for the patient. 
                       
  Parameter Significance Tests Section (Reference Group: OUTCOM = Mortality) 
 Regression  Wald Wald Odds 
 Coefficient Standard Z-Value Prob Ratio 
Parameter (B or Beta) Error (Beta=0) Level Exp(B) 
B0: Intercept 1.463776 0.697 2.1 0.036 4.32 
B1: (FITS | no - yes) 
 0.9529916 0.400 2.4 0.017 2.59 
B2: (LEV_CON | nor - low) 
 1.674743 0.320 5.2 0.000 5.34 
B3: (SMOKER | no - yes) 
 0.7970119 0.343 2.3 0.020 2.22 
B4: (TB | prev - current) 
 -1.144894 0.658 -1.7 0.082 0.32 
B5: (TB | no - current) 
 3.364215 1.051 3.2 0.001 28.91 
B6: (TRT_ADH | yes - no) 
 0.8650325 0.368 2.3 0.019 2.38 
B7: (TRT_REG | ambd - fluco) 
 1.112342 0.537 2.1 0.038 3.04 
B8: (TRT_REG | both - fluco) 
 0.1242402 0.655 0.2 0.850 1.13 
B9: (TRT_REG | nu - fluco) 
 -0.7403251 1.195 -0.6 0.536 0.48 
   
Odds ratio analysis reveal that, keeping other variables constant, patients not having had cases of 
tuberculosis before are about 29 times more likely to survive compared to those with current cases of 
tuberculosis. Also, those who are conscious or not confused are 5 times likely to survive compared to 
those who are unconscious or confused. The use of Amphotericin B regimen is 3 times more 
effective in saving a patients’ life compared to fluconazole. Patients not presented with Fits are more  
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than twice as likely to survive compared to patients with Fits as a presenting symptom. Finally non-
smokers and those adhering to their treatment schedule will be doubling their chances of survival 
compared to smokers and others who abscond from their treatment routine. 
 
  Odds Ratios Section (Reference Group: OUTCOM = Mortality) 
 
 Regression Odds Lower 95% Upper 95% 
 Coefficient Ratio Confidence Confidence 
Parameter (B or Beta) Exp(B) Limit Limit 
B0: Intercept 1.463776 4.32 1.10 16.93  
B1: (FITS | no - yes) 
 0.9529916 2.59 1.18 5.68  
B2: (LEV_CON | nor - low) 
 1.674743 5.34 2.85 9.99  
B3: (SMOKER | no - yes) 
 0.7970119 2.22 1.13 4.34  
B4: (TB | prev - current) 
 -1.144894 0.32 0.09 1.16  
B5: (TB | no - current) 
 3.364215 28.91 3.68 226.89  
B6: (TRT_ADH | yes - no) 
 0.8650325 2.38 1.15 4.89  
B7: (TRT_REG | ambd - fluco) 
 1.112342 3.04 1.06 8.72  
B8: (TRT_REG | both - fluco) 
 0.1242402 1.13 0.31 4.09  
B9: (TRT_REG | nu - fluco) 
   -0.7403251            0.48            0.05            4.97  
 
                                            Classification Table 
 Estimated 
Actual 0 1 Total 
0 21 10 31 
1 6 200 206 
Total 27 210 237 
 
Percent Correctly classified = 93.2% 
 
It can be seen from the classification table that 93.2% of the study data were correctly classified by 
this model. 
 
  Estimated Logistic Regression Model for Survival 
 






 )(1
)(
survivalp
survivalp
Log = 1.46 + 0.95*FITS (no) + 1.67*LEV_CON (nor) + 0.80*SMOKER (no) + 3.36*TB (no) +   
                                                0.87*TRT_ADH (yes) + 1.11*TRT_REG (ambd). 
  
Note that each model estimates B for a specific group, where Logit(Y) = XB. To calculate a 
probability, transform the logit using Prob(Y<>group) = 1/(1+Exp(-XB)) or Prob(Y=group) = Exp(-
XB)/(1+Exp(-XB)). 
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                 Area under ROC Curve c = 0.942 
 
According to Gelman & Hill, (2007) the R-square is not a proper tool to assess a non-linear 
model like the logistic regression model. Hence, it was ignored. 
                     
                       Association of Predicted Probabilities and Observed Responses 
  Percent Concordant       93.2     Somers' D     0.887 
                         Percent Discordant        4.9     Gamma         0.900 
                         Percent Tied              1.5     Tau-a         0.202 
                         Pairs                     6386     c             0.942 
 
 
                                  Hosmer and Lemeshow Goodness-of-Fit Test 
 
                                Chi-Square         DF         Pr > ChiSq 
      5.4378            8                0.7099 
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AREA UNDER THE ROC CURVE = 0.942 
Hosmer and Lemeshow test of goodness of fit verifies the correctness of the model 
formulation. 
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Hosmer-Lemeshow goodness-of-fit test statistic greater than .05 implies a good fit and the 
null hypothesis will not be rejected. This will mean that there is no difference between 
observed and model-predicted values. That is to say those well-fitting models are not 
significant on the Hosmer-Lemeshow goodness-of-fit test and that indicates model prediction 
that is not significantly different from observed values. Hence, with 7099.02 LemeshowHosmer  
for the survival model, it is evident that the model fits the data well. 
Furthermore, the Somers Dxy rank correlation measures the correlation between the predicted 
probabilities and the observed outcome. A Dxy =1 indicates that the model discriminates 
perfectly. The 0.887 value for Somers’ Dxy shows a strong correlation between the predicted 
probabilities and the observed outcome. This also confirms that the model has good 
predictive power.  
The table of concordant, discordant, and tied pairs is calculated by pairing the observations 
with different response values. Here in this study, 206 patients survived and 31 patients died, 
resulting in 206 * 31 = 6386 pairs with different response values for which 93.2% of them are 
concordant.  
The summary from the table of concordant and discordant values as reflected by the Somers' 
D (0.887), Goodman-Kruskal Gamma (0.900), and Kendall's Tau-a (0.202) indicate that the 
model predicts well. 
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 4.3 Presenting Symptoms of Cryptococcal Meningitis 
 
Table 4.6 Comparing Presenting Symptoms in this Study with those of other Studies 
 CURRENT   
   STUDY 
E. LONDON 
Lightowler  
    et al.  
DURBAN 
Moosa & 
Coovadia. 
DURBAN 
McCarthy  
   et al  
GAUTENG 
Salima  
  et al. 
KENYA 
Mohammed & 
Chandrasekhara 
INDIA 
HEADACHE 94.1 84.4 84 78 94 95 
FEVER 19.8 17.7 48 55 63 70 
VOMITING 50.6 45.7 N/A 41 N/A 76 
NECK 
STIFFNESS 
51.5 76.9 93 69 64 N/A 
FITS   7.5   8.1 16 N/A 53 N/A 
CONFUSION 27.4 22.6 36 N/A 47 N/A 
 
The table shows that 94.1% of the patients had headache. This tallied with Salima, et al., 
(2011) and Mohammed & Chandrasekhara, (2009) which had 94% and 95% respectively. 
However, contrary to the much reported findings that Headache is a predictor of survival, the 
variable Headache was not found significant in this study. Neck stiffness and Vomiting were 
neck and neck with values of 51.5% and 50.6% respectively. The percentage value for 
Vomiting is quite close to the result from Lightowler, J V J; Cooke, G S; Mutevedzi, P; 
Lessells, R J; Newell, M L; et al, (2010) but much less than the values obtained by 
Mohammed & Chandrasekhara, (2009) in their study in India. For Neck stiffness, the 
percentage values obtained in Lightowler, J V J; Cooke, G S; Mutevedzi, P; Lessells, R J; 
Newell, M L; et al, (2010); Moosa & Coovadia, (1997); McCarthy, K M; Morgan, J; 
Wannemuehler, K A; Mirza, S A;et al, (2003) and Salima, et al., (2011) were quite higher 
compared to the study result. It is important to note that the first two studies were done in the 
city of Durban in South Africa, yet all their values with the exception of Headache differed.  
However, comparing this study with Lightowler, Headache was the most predominant 
symptom followed by Neck stiffness (just like in other studies). The two studies were also in 
agreement that Vomiting was the next, followed by Confusion; Fever and lastly, Fits.  
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     CHAPTER FIVE 
5.0 DISCUSSION OF RESULTS AND CONCLUSION  
This chapter presents and discusses the findings from this research study. It also examines 
whether the research objectives were met and the research questions well answered. Finally 
this chapter also present a conclusion, based on the findings of this study.  
 
5.1 Discussion 
The primary objectives of this research study were to identify the outcome predictors for 
Cryptococcal Meningitis and the predominant presenting symptoms among patients with 
Cryptococcal Meningitis. The secondary objective was to examine the extent of conformity 
of the results of this study with the research studies done previously on this subject.  
To meet the primary and secondary objectives of this research study, there are questions that 
must be answered by the results emerging from it. They include: 
 What are the outcome predictors of Cryptococcal Meningitis among the patients’ 
whose information were included in this study? 
 What are the predominant presenting symptoms indicative of Cryptococcal 
Meningitis among these patients? 
 Does the result from 1 and 2 confirm the correctness of similar studies done 
elsewhere?  
Univariable analysis of initial variables gave the following variables which were significantly 
associated with an outcome of Cryptococcal Meningitis: Level of Consciousness at the time 
of admission (Lev_con); Tuberculosis; Treatment adherence (Trt_adh); Stopping the use of 
Amphotericin B (Amb_stp); Duration on Amphotericin B (Donamb); Smoking (Smoker); 
Fits as a presenting symptom (Fits); Confusion as a presenting symptom (Conf); Treatment 
Regimen used (Trt_reg). 
The variables Smoker, Lev_con, Tb, Trt_adh, Fits, Conf and Trt_reg were further examined 
in a multiple Logistic regression. Amb_stp, Donamb and Dofadm were all dropped from the 
multivariable logistic regression as they were considered to be surrogates for the effect of 
Trt_reg. 
By comparing the research results with the research objectives and questions, the following 
conclusions were drawn: 
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The patient’s level of Consciousness (p=0.000; OR=5.34; CI=2.85-9.99), Tuberculosis 
(p=0.001 OR=28.91 CI=3.68-226.89), Treatment adherence or compliance attitude (p=0.019; 
OR=2.38; CI=1.15-4.89), Fits (p=0.017; OR=2.59; CI=1.18-5.68) and Smoking (p=0.020 
OR=2.22 CI=1.13-4.34) are reliable outcome predictors for Cryptococcal Meningitis and can 
therefore be used for prognosis of the infection. Confusion considered in the absence of an 
altered consciousness was found to be significantly associated with CM outcome. The use of 
Amphotericin B regimen (p=0.038 OR=3.04 CI=1.06-8.72) for the 14 days period was found 
effective in relation to the survival of the patient compared to the use of fluconazole 
monotherapy or a combination of both therapies within the first 14 days of admission.  
Although the order of impact of the variables on the mortality and survival of patients has 
been outlined in chapter 4, a Glasgow Coma score <15 (p=0.000; OR=5.34; CI=2.85-9.99) 
was found to be the most powerful factor that influences mortality and a Glasgow Coma 
score of 15 (p=0.000; OR=5.34; CI=2.85-9.99) was the most powerful factor predicting a 
patients’ survival as well. Patients with lowered level of consciousness were found 5 times at 
risk of dying compared to patients with normal consciousness keeping other variables 
constant. However, patients with current cases of tuberculosis are 9 times and 29 times more 
likely to die compared to patients with previous cases of tuberculosis and patients with no 
history of tuberculosis respectively. Also non-adherence to treatment or not having a 
treatment compliance attitude doubles the chances of dying for such patient compared to 
patients that comply with treatment. Presenting with Fits or Smoking at the time of admission 
also doubles the likelihood of the patient dying compared to patients not presented with Fits 
or not smoking. Although not statistically significant, the use of Fluconazole as a first line of 
therapy within the first 14 days of in-hospital treatment was seen to be associated with 
mortality. Being confused was also found to be a strong predictor of mortality in the absence 
of altered consciousness. 
On the other hand, Multivariable logistic regression indicates that been conscious 
(p=0.000;OR=5.34;CI=2.85-9.99), no history of tuberculosis (p=0.001; OR=28.91; CI=3.68-
226.89), adhering to prescribed treatment and guidelines (p=0.019; OR=2.38; CI=1.15-4.89), 
no Fits (p=0.017; OR=2.59; CI=1.18-5.68) and not having smoked before (p=0.020; 
OR=2.22; CI=1.13-4.34) were all reliable predictors of patients’ survival and can be used in 
the prognosis of the infection. Also, the uninterrupted use of Amphotericin B (p=0.038; 
OR=3.04; CI=1.06-8.72) as a first line treatment for CM patients was found to be associated 
with survival.       
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Patients treated with Amphotericin B as first line of therapy compared to Fluconazole were 
found 3 times more likely to survive. 
On the presenting symptoms, the order of predominance from top to the least include: 
Headache (94.1%), Neck-stiffness (51.5%), Vomiting (50.6%), Confusion (27.4%), Fever 
(19.8%) and Fits (7.5%). In a Univariable analysis of variables, Headache was found not to 
be significantly associated with CM contrary to submissions from many publications that 
presenting with headache is significantly associated with patients’ survival. However, the 
result of this study failed to uphold such submissions. However, it found that Fits and 
Confusion are the only symptoms among those considered in this study that are associated 
with CM outcomes. When present, they increase the patient chances of dying and when 
absent, the patient’s chances of survival improve. 
 
5.2 Conclusion 
In concluding this dissertation, it is imperative to note that this study considered the records 
of patients who had laboratory confirmed cases of CM and were admitted for treatment at the 
facilities of the East London Hospital Complex. Though it is the first of its kind carried out at 
the East London Hospital Complex and maybe the first in the Eastern Cape of South Africa, 
there may be the tendency to generalize the result to reflect a situation in the province, 
however in doing this, adequate precaution should be taken in view of the fact that 
submissions from many published works clearly indicate that factors influencing the outcome 
of treatment for CM may vary from place to place. This is also evident in this study 
especially with the presenting symptoms. Some publications found that neck-stiffness and 
headache are statistically significant where as for this study, they are not. However, the 
findings of this study and the statistical model may be useful in prognosis of Cryptococcal 
Meningitis cases of patients been treated at the East London Hospital Complex given that the 
in-hospital care standard remain unchanged. 
It is important that a prospective study be carried out to confirm the finding in this study that 
headache is not associated with survival or mortality among CM patients but an indication of 
the presence of the infection. On this premise, it should be wise that clinicians at ELHC avoid 
using headache as a prognostic factor for CM patients but rather use other factors like 
consciousness, fits, confusion, Tuberculosis, social habits like smoking and adherence to  
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treatments which were found significantly associated with CM outcomes in this study to 
predict CM outcomes. 
People living with HIV/AIDS and others at risk of CM infection should be educated on the 
symptoms of the disease using the predominant symptoms of the disease (as outlined in this 
study) as a way of assisting them seek treatment at a hospital facility on time. Although 
Headache, Vomiting and Neck-stiffness were the 3 most prominent symptoms in this 
research study, no significant association between them and CM outcomes were established.   
It is also important to note that HIV/AIDS was not found significantly associated with CM 
but can be seen from the data frequency which indicates that 92 % of patients were HIV 
positive; that been HIV positive is a risk factor for CM infection and not an outcome 
predictor for the infection. Demographic factors were not significant in the study. 
Finally it is important to note that the results of this study agreed with some findings from 
previous publications but differed in other aspects. The significant association between  
Tuberculosis and CM outcomes agreed with Lightowler, J V J; Cooke, G S; Mutevedzi, P; 
Lessells, R J; Newell, M L; et al, (2010) (TB current; p=0.02). The findings of Azure, M; et 
al, (2010) also confirmed the finding that headache is not significantly associated with CM 
outcome. The patients’ level of consciousness (p=0.000; OR=5.34; CI=2.85-9.99), is in 
tandem with Canessa, J; Cabrera, D; Eskenazi, J; Samalvides, F; (2011) who submitted that 
Glasgow at admission was (OR = 4.55 (1.61 – 12.20), p = 0.01). The significance of 
Treatment adherence in the model confirms the submission from Collett & Parrish, (2007). 
Also the finding that Fits and Confusion are significantly associated with mortality differed 
with the findings from Azure, M; et al, (2010) who submitted that none of the symptoms 
were found significant in the study they carried out in Zimbabwe.  
Lastly, this dissertation can be concluded by submitting that the prognostic factors for CM 
vary partly from one geographical area to another and it will be wise that a study of this type 
be conducted in various geographical areas in order to provide information that will match 
the prognosis of Cryptococcal meningitis in such areas. 
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APPENDICES 
APPENDIX A:  DATA PRE-EXTRACTION FORM USED ON ADMISSION BOOK (35 COLS) 
SURNAME AND 
INITIALS 
FOLDER NO. DIAGNOSIS ADM 
DATE 
DISCH 
DATE 
OUT 
COME 
LOCALITY 
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APPENDIX B: CASE RECORD FORM 
            DATA EXTRACTION FORM FOR RETROSPECTIVE CLINICAL STUDY  
CENTRE CODE  
PATIENT’S CODE  
                                               PATIENT’S DEMOGRAPHICS 
MEASURED 
VARIABLES 
LEVELS OF 
VARIABLES 
                                             BASELINE 
   
AGE  
GENDER MALE  
FEMALE  
RACE BLACK  
INDIAN  
COLOURED  
WHITE  
NONE  
LOCALITY INFORMAL 
SETTLEMENT 
 
TOWNSHIP  
SUBURB  
UPMARKET  
SOCIO-
ECONOMIC 
STATUS 
EMPLOYED  
UNEMPLOYE
D 
 
SMOKER YES  
NO  
 DIABETIC YES  
NO  
NO RECORD  
T.B CURRENTLY  
PREVIOUSLY  
NONE  
NO RECORD  
LENGTH OF TIME TO FIRST 
TREATMENT ON 
ADMISSION 
 
TREATMEN
T REGIMEN 
 BASELINE 
AmBd  
FLUCONAZO
LE 
 
BOTH  
                                               CRYPTOCOCCAL MENINGITIS INFORMATION 
ADMISSION DATE  
SYMPTOMS 
 
 
 
 
 
 
HEADACHE  
FEVER  
FITS  
CONFUSION  
VOMITING  
STIFF NECK  
OTHERS  
  
  
 
 
 
CSF PRESSURE  
LEVEL OF 
CONSCIOUS
 BASELINE 
NORMAL  
NESS ON 
ADMISSION 
LOW  
SYSTOLIC BP  
DIASTOLIC BP  
DATE OF DISCHARGE  
                                                          HIV/AIDS INFORMATION 
HIV STATUS POSITIVE  
NEGATIVE  
UNKNOWN  
ON ART 
BEFORE 
C.M 
YES  
NO  
IF YES, FOR HOW LONG?  
WAS ART 
STOPPED IN 
THE 
COURSE OF 
C.M TRT 
 
YES 
 
NO  
ADHERENC
E TO 
HOSPITAL 
APPOINTME
NTS 
FULLY  
PARTLY  
NO  
                                                 AmBd TREATMENT INTERRUPTIONS 
WAS AmBd 
STOPPED 
BEFORE  14 
DAYS 
 
YES 
 
 
NO  
REASON FOR STOPPING 
AmBd 
 
DURATION ON AmBd 
BEFORE OUTCOME 
 
                                                                  SERUM CHEMISTRY 
CREATININ
E 
 
UREA  
HAEMOGLO
BIN 
 
POTASSIUM  
CD 4 
COUNT 
 
PROTEIN  
GLUCOSE  
SODIUM  
  
TIME TO 
RELAPSE 
 
                                                                              OUTCOME 
OUTCOME SURVIVED  
DIED  
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APPENDIX C: ETHICS CLEARANCE CERTIFICATE 
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   APPENDIX F: CODEBOOK 
 
 
Smoker:           1= Smoker of cigarette;  0= Not smoking 
TB: Tuberculosis:     
                                   Current = still having TB;      Prev = Had TB b/4 and was treated;    
                                No = Never had TB 
TB_CURR:         Current case of Tuberculosis 
Trt_Reg:  Treatment regimen used for the patient during the intensive phase of the treatment process.                      
                                 A= Amphotericin B; F = Fluconazole; BOTH = A and F; and                              
                                 N or Noam_fl = No A or F or Both were used 
Fits:                          0 = Patient had no fits; 1= Patient had fits 
Conf=Confusion:      0 = Patient do not appear confused;  1= Patient seems confused 
Lev_Con=Level of Consciousness as at the time of admission (baseline)                             
                      Nor = Normal or a Glasgow coma score of 15; 
                                 Low = Abnormal mental status, confused or Glasgow coma score <15; 
Dofadm = The number of days the patient spent at the hospital (from time of admission to discharge).  
On_Art = If the patient is HIV positive, was he/she on Anti-Retroviral Treatment prior to the CM  
                 Infection or hospital admission? 
Trt_Adh = Treatment adherence: Patient’s compliance with the treatment guidelines given to 
        Him/her. 
AmB_Stp = Was Amphotericin B stopped before the 14th day? 
Donamb = If patient was changed from Amphotericin B, how long was the patient treated with  
                  Amphotericin B before the change? 
Outcom = Outcome: The endpoint of the patient’s in-hospital treatment  
           1=survival;  0=death 
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APPENDIX G: SAS PROGRAM FOR THE UNIVARIABLE LOGISTIC ANALYSES 
data amb_stp; 
input amb_stp$ outcome$ count; 
datalines; 
no died 4 
no survived 121 
yes died 27 
yes survived 85 
; 
run; 
proc print data= amb_stp; 
run; 
proc freq data=amb_stp; 
weight count 
tables amb_stp*outcome/chisq; 
run; 
proc logistic data=amb_stp; 
weight count; 
class amb_stp (ref="no")/param=ref; 
model outcome(event="died")=amb_stp/rsquare corrb; 
run; 
data amb_stp; 
input amb_stp$ outcome$ count; 
datalines; 
no died 4 
no survived 121 
yes died 27 
yes survived 85 
; 
run; 
proc print data= amb_stp; 
run; 
proc freq data=amb_stp; 
weight count 
tables amb_stp*outcome/chisq; 
run; 
proc logistic data=amb_stp; 
weight count; 
class amb_stp (ref="yes")/param=ref; 
model outcome(event="survived")=amb_stp/rsquare corrb; 
run; 
data confusion; 
input confusion$ outcome$ count; 
datalines; 
yes died 15 
yes survived 50 
no died 16 
no survived 156 
; 
run;      74 
proc print data=confusion; 
run; 
proc freq data=confusion; 
weight count; 
tables confusion*outcome/chisq; 
run; 
proc logistic data=confusion; 
weight count; 
class confusion(ref="no")/ param=ref; 
model outcome(event="died")=confusion/rsquare; 
run; 
data confusion; 
input confusion$ outcome$ count; 
datalines; 
yes died 15 
yes survived 50 
no died 16 
no survived 156 
; 
run; 
proc print data=confusion; 
run; 
proc freq data=confusion; 
weight count; 
tables confusion*outcome/chisq; 
run; 
proc logistic data=confusion; 
weight count; 
class confusion(ref="yes"); 
model outcome(event="survived")=confusion/rsquare; 
run; 
data dofadm; 
input dofadm$ outcome$ count; 
datalines; 
1-7days died 19 
1-7days survived 17 
8-14days died 3 
8-14days survived 56 
15-21days died 5 
15-21days survived 89 
>=22days died 4 
>=22days survived 44 
; 
run; 
proc print data=dofadm; 
run; 
proc freq data=dofadm; 
weight count; 
tables dofadm*outcome/chisq; 
run;      75 
proc logistic data=dofadm; 
weight count; 
class dofadm (ref=">=22days")/param=ref; 
model outcome=dofadm/rsquare corrb; 
run; 
data dofadm; 
input dofadm$ outcome$ count; 
datalines; 
1-7days died 19 
1-7days survived 17 
8-14days died 3 
8-14days survived 56 
15-21days died 5 
15-21days survived 89 
>=22days died 4 
>=22days survived 44 
; 
run; 
proc print data=dofadm; 
run; 
proc freq data=dofadm; 
weight count; 
tables dofadm*outcome/chisq; 
run; 
proc logistic data=dofadm; 
weight count; 
class dofadm (ref="1-7days")/param=ref; 
model outcome(event="survived")=dofadm/rsquare corrb; 
run; 
data don_amb; 
input don_amb$ outcome$ count; 
datalines; 
1-7days died 21 
1-7days survived 43 
8-13days died 5 
8-13days survived 41 
14days died 4 
14days survived 121 
unknown died 1 
unknown survived 1 
; 
run; 
proc print data=don_amb; 
run; 
proc freq data=don_amb; 
weight count; 
tables don_amb*outcome/chisq; 
run; 
proc logistic data=don_amb; 
weight count;     76 
class don_amb (ref="14days")/param=ref; 
model outcome(event="died")=don_amb/rsquare corrb; 
run; 
data don_amb; 
input don_amb$ outcome$ count; 
datalines; 
1-7days died 21 
1-7days survived 43 
8-13days died 5 
8-13days survived 41 
14days died 4 
14days survived 121 
unknown died 1 
unknown survived 1 
; 
run; 
proc print data=don_amb; 
run; 
proc freq data=don_amb; 
weight count; 
tables don_amb*outcome/chisq; 
run; 
proc logistic data=don_amb; 
weight count; 
class don_amb (ref="14days")/param=ref; 
model outcome(event="died")=don_amb/rsquare corrb; 
run; 
proc logistic data=don_amb; 
weight count; 
class don_amb (ref="1-7days")/param=ref; 
model outcome(event="survived")=don_amb/rsquare corrb; 
run; 
data fits; 
input fits$ outcome$ count; 
datalines; 
no died 24 
no survived 195 
yes died 7 
yes survived 11 
; 
run; 
proc print data=fits; 
run; 
proc freq data=fits; 
weight count; 
tables fits*outcome/chisq; 
run; 
proc logistic data=fits; 
weight count; 
class fits;     77 
model outcome=fits/rsquare; 
run; 
data h_ache; 
input h_ache$ outcome$ count; 
datalines; 
yes died 30 
yes survived 193 
no died 1 
no survived 13 
; 
run; 
proc print data=h_ache; 
run; 
proc freq data=h_ache; 
weight count; 
tables h_ache*outcome/chisq; 
run; 
proc logistic data=h_ache; 
weight count; 
class h_ache; 
model outcome=h_ache/rsquare; 
run; 
data lev_con; 
input lev_con$ outcome$ count; 
datalines; 
low died 22 
low survived 29 
normal died 9 
normal survived 177 
; 
run; 
proc print data=lev_con; 
run; 
proc freq data=lev_con; 
weight count; 
tables outcome*lev_con/chisq; 
run; 
proc logistic data=lev_con; 
weight count; 
class lev_con; 
model outcome=lev_con/rsquare; 
run; 
data smok_st; 
input smok_st$ outcome$ count; 
datalines; 
non-smoker died 21 
non-smoker survived 171 
smoker died 10 
smoker survived 35 
;      78 
run; 
proc print data=smok_st; 
run; 
proc freq data=smok_st; 
weight count; 
tables outcome*smok_st/chisq; 
run; 
proc logistic data=smok_st; 
weight count; 
class smok_st; 
model outcome = smok_st/rsquare; 
run; 
data tb; 
input tb$ outcome$ count; 
datalines; 
no died 1 
no survived 98 
previous died 5 
previous survived 35 
current died 25 
current survived 73 
; 
run; 
proc print data=tb; 
run; 
proc freq data=tb; 
weight count; 
tables tb*outcome/chisq; 
run; 
proc logistic data=tb; 
weight count; 
class tb (ref="no")/param=ref; 
model outcome (event="survived")=tb/rsquare corrb; 
run; 
data tb; 
input tb$ outcome$ count; 
datalines; 
no died 1 
no survived 98 
previous died 5 
previous survived 35 
current died 25 
current survived 73 
; 
run; 
proc print data=tb; 
run; 
proc freq data=tb; 
weight count; 
tables tb*outcome/chisq;   79 
run; 
proc logistic data=tb; 
weight count; 
class tb (ref="current")/param=ref; 
model outcome (event="survived")=tb/rsquare corrb; 
run; 
data trt_adh; 
input trt_adh$ outcome$ count; 
datalines; 
no died 27 
no survived 128 
yes died 4 
yes survived 78 
; 
run; 
proc print data=trt_adh; 
run; 
proc freq data=trt_adh; 
weight count; 
tables trt_adh*outcome/chisq; 
run; 
proc logistic data=trt_adh; 
weight count; 
class trt_adh; 
model outcome=trt_adh/rsquare; 
run; 
data trt_reg; 
input trt_reg$ outcome$ count; 
datalines; 
ambd died 18 
ambd survived 156 
f_azole died 4 
f_azole survived 27 
both died 5 
both survived 22 
noam_fl died 4 
noam_fl survived 1 
; 
run; 
proc print data=trt_reg; 
run; 
proc freq data=trt_reg; 
weight count; 
tables trt_reg*outcome/chisq; 
run; 
proc logistic data=trt_reg; 
weight count; 
class trt_reg(ref="ambd") outcome/ param=ref; 
model outcome(event="died")=trt_reg/rsquare corrb; 
run;      80 
data trt_reg; 
input trt_reg$ outcome$ count; 
datalines; 
ambd died 18 
ambd survived 156 
f_azole died 4 
f_azole survived 27 
both died 5 
both survived 22 
noam_fl died 4 
noam_fl survived 1 
; 
run; 
proc print data=trt_reg; 
run; 
proc freq data=trt_reg; 
weight count; 
tables trt_reg*outcome/chisq; 
run; 
proc logistic data=trt_reg; 
weight count; 
class trt_reg(ref="noam_fl") outcome/ param=ref; 
model outcome(event="survived")=trt_reg/rsquare corrb; 
run; 
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